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Endogenous retroviruses (ERVs) make up a significant portion of vertebrate 
genomes, and serve as a fossil record of past retroviral infections. Although most 
ERV genes acquire inactivating mutations over time, some loci retain open 
reading frames (ORFs) across one or more of the viral genes. The ERV-Fc 
family, for example, endogenized in multiple mammalian hosts 10 to 30 million 
years ago, yet many copies maintain intact ORFs corresponding to the env gene, 
including loci in humans (HERV-Fc1-env) and baboons (babERV-Fc2-env). We 
previously identified intact ERV-Fc-related env sequences in eight additional 
mammalian species: chimpanzee, bonobo, aardvark, grey mouse lemur, squirrel 
monkey, marmoset, dog, and panda. Here we present the results of our assays 
of expression of these full-length Env proteins. We found that most of the 
precursors were not cleaved to form the functional surface (SU) and 
transmembrane (TM) subunits, even when a canonical furin cleavage site was 
still intact.  An exception was babERV-Fc2, in which reconstruction of the 
cleavage site led to cleavage into SU and TM subunits. Furthermore, removal of 
22 residues from the C-terminus of the cytoplasmic tail of babERV-Fc2 enhanced 
syncytia formation and the ability of babERV-Fc2 pseudotyped virions to infect 
293T cells, suggesting the presence of an R-peptide cleavage mechanism. A 
survey of a small panel of cells revealed that only human cell lines were 
infectable by babERV-Fc2 pseudotyped murine leukemia virus (MLV) particles, 
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whereas cells of old world monkey, canine, feline and chicken origin were not 
susceptible to infection. Ectopic expression of native Env codon optimized 
babERV-Fc2 Env can also inhibit infection by reconstructed babERV-Fc2 
pseudotyped virus, raising the possibility that the endogenous glycoprotein 
encoded in the baboon genome may function as a viral entry inhibitor.  Our 
results suggest that exaptation of ERV Env proteins as antiviral defense genes 
involves a combination of selective pressures:  selection to preserve the 
receptor-binding and receptor interference functions of Env, but also selection to 
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 The Retroviridae is a family of viruses, known as retroviruses, that are 
characterized by the ability to reverse transcribe their positive-strand (+) 
ribonucleic acid (RNA) genome into a deoxyribonucleic acid (DNA) copy, which is 
then integrated into the host genome.  This integrated DNA genome is then 
known as a provirus.  Retroviruses are widespread and can infect many 
vertebrates.  Retroviruses have enveloped virions, with envelope proteins (Env) 
studding the surface; within there is a capsid core that protects the two copies of 
the RNA genome and contains the viral enzymes (Fig. 1.1) [1].  All retrovirus 
RNA genomes have four standard genes: group-specific antigen (gag), protease 
(pro), polymerase (pol) and envelope (env). These genes are flanked on the 5’ 
side by the repeat sequence (R), the unique 5’ sequence (U5), the primer binding 
sequence (PBS) and a packaging signal. On the 3’ side they are bordered by a 
polypurine tract (PPT), the unique 3’ sequence (U3) and R (Fig. 1.2 and 1.3) 
[1].  The RNA genome has a 5’ cap and a 3’ poly-A tail.  
Life Cycle 
The retroviral life cycle begins with the Env protein recognizing and 
binding to a cell surface receptor. The Env is expressed as a polyprotein that is 
cleaved into two subunits, a surface subunit (SU) and a transmembrane subunit 
(TM).  SU is responsible for receptor recognition.   A conformational change is 
induced either by receptor binding, or for viruses that enter via endocytosis, by a 




























Figure 1.1: The retroviral life cycle. In the top left corner is a representation of 
a mature retrovirus, CA=capsid (red), IN=integrase (purple), RT=reverse 
transcriptase (light blue), PR=protease (dark gray), Env=envelope (green) 
(SU=surface subunit, TM=transmembrane domain). Arrows follow the viral life 
cycle starting with Env recognition of a receptor and ending with release and 
maturation of a new viral particle.  
	
	 4	
becomes inserted into the host cell membrane; fusion then permits entry of the 
viral core into the cytoplasm (Fig. 1.1) [1], [2].  This fusion process can take place 
at the cell surface or after endocytosis of the virus.  After entry of the viral core 
into the cytoplasm, reverse transcription of the RNA genome into the DNA 
genome begins, and takes place in a large complex called the pre-integration 
complex (PIC). Reverse transcriptase (RT) is the major enzyme involved in this 
process [1], [3]–[5] (Fig. 1.1).  There is a small amount of uncoating of the core 
that has to occur for reverse transcription to happen, but the process and how 
much is poorly understood.  Reverse transcription starts with binding a primer 
transfer RNA (tRNA) to a complementary PBS on the plus strand RNA genome 
(Fig. 1.2).  The RT then binds to the primer and minus strand (-) DNA synthesis 
occurs towards the 5’ end producing the U5 and R sequences, the RNA template 
is degraded by ribonuclease H (RNase H) activity after it is copied into DNA (Fig. 
1.2).  This fragment of DNA then “jumps” to the 3’ end of the viral genome, where 
the R sequence anneals to the complementary R sequence at the 3’ end.  DNA 
synthesis will continue and stop at the PBS (Fig. 1.2).  To synthesize the (+) 
strand of DNA the PPT, which is mostly resistant to the RNase H activity, serves 
as the primer binding spot (Fig. 1.2).  DNA synthesis occurs toward the 5’ end, 
copying the U3, R and U5, the tRNA primer is removed and there is a second 
translocation step (Fig. 1.2).  The DNA then anneals to the complementary PBS 
on the other side of the strand and RT catalyzes the elongation of the remaining 









R U5 PBS gag pro pol env PPT U3 R
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R U5 PBS gag pro pol env PPT U3 R U5
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R U5 PBS gag pro pol env PPT U3 R U5U3




DNA synthesis  
Figure 1.2:  Major steps of reverse transcription. Orange 
lines represent RNA, dashed orange lines indicate 
degrading RNA and green lines represent DNA. R = repeat 
region, U5 = unique 5’ sequence, PBS = primer binding 
sequence, gag = group-specific antigen, pro = protease, 
pol = polymerase, env =envelope, PPT = polypurine tract, 

















5’ LTR 3’ LTRgag pro pol env
Figure 1.3: Representation of a simple retrovirus provirus and a gamma Env.  
Top figure is a representation of a simple retroviral provirus with LTR’s 
flanking the gag, pro, pol and env genes. Blown up below is a typical 
gammaretrovirus Env.  Light gray=surface unit (SU), gray=transmembrane 
domain (TM), green=signal peptide (SP), blue bar=isomerization domain, 
light orange=fusion peptide (FP), light blue=immunosuppressive domain 
(ISD), yellow=CX6CC motif, dark orange=membrane spanning domain 
(MSD) and purple=R-peptide. The SU and TM are cleaved at the furin 
cleavage site by furin.      
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repeats (LTRs) at either end that respectively contain the U3, R and U5 (Fig. 1.2 
and 1.3) [1].   
After reverse transcription, the DNA genome is trafficked to the nucleus 
(Fig. 1.1).  The mechanism of nuclear entry is not well known, but most 
retroviruses require the cell to go through mitosis and for the nuclear envelope to 
breakdown before entry occurs [1], [6]–[9]. Though, lentiviruses can infect non-
dividing cells, suggesting they are able to cross an intact nuclear envelope [1], 
[6], [10], [11].  The DNA viral genome is then integrated into the host genome; 
this process is mediated by the viral protein integrase (IN) (Fig. 1.1).  Integrase 
removes two nucleotides from the 3’ ends of the viral DNA genome creating an 
overhang.  A double strand DNA break, with an overhang, is then introduced in 
the host genome by IN.  A new phosphodiester bond is created between the host 
genome and the viral genome, the overhanging 5’ viral DNA is not integrated into 
the host DNA.  After integration, there are short gaps in the host genome that are 
repaired by the host DNA repair machinery, resulting in short duplication sites 
that flank the provirus, which can be anywhere from 4-6bp long depending on the 
retrovirus [1].  The provirus is then a permanent part of the host cell genome (Fig. 
1.1).  
 Production of new virions from the provirus through transcription and 
translation is mediated by host enzymes.  The U3 contains a promoter that is 
recognized by RNA polymerase II. Transcription starts at U3-R of the 5’ LTR, the 
RNA is capped and polyadenylated, which generates a new RNA viral genome or 
messenger RNA (mRNA) to be used as a template for translation the viral 
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proteins [1].  The RNA genomes are trafficked out of the nucleus and will take 
several pathways (Fig. 1.1).  Some will be trafficked directly to sites of virion 
assembly, to be used as a new genome.  Other copies will be used to produce 
the Gag and Gag-Pro-Pol polyproteins, and another copy will be spliced to yield 
mRNA splice variants for the Env protein and accessory proteins, if any are 
present (Fig. 1.1).  The viral proteins produced will be trafficked to the cell 
membrane where viral assembly typically occurs (Fig. 1.1).  The Gag, Pro and 
Pol proteins are expressed in a complex manner which differs between the 
various types of retroviruses; they are translated into a polyprotein that is 
processed during the maturation stage of the viral life cycle. Because more Gag 
is needed than Pro or Pol, retroviruses have evolved two main mechanisms to 
limit the amount of the polyprotein produced.  The first is translational 
readthrough, in which the gag, pro and pol ORFs are in the same reading frame 
but are separated by a stop codon.  In most instances translation only produces 
Gag protein.  About 5% to 10% of the time translation does not cease at the stop 
codon but instead continues to translate the RNA through the entire length to 
produce the Gag-Pro-Pol precursor protein [1]. The second mechanism used by 
retroviruses to regulate the ratios of Gag, Pro and Pol is through translational 
frameshifting.  This occurs when the gag, pro and pol genes are in different 
reading frames.  Most occurrences result in only Gag being produced, but 
approximately 10% of the time the ribosome will slip back a nucleotide and 
continue in the new reading frame to produce the Gag-Pro-Pol polyprotein [1]. 
The pro reading frame, depending on the virus, can be part of gag, part of pol or 
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in its own reading frame.  The production of Gag, Pro and Pol occurs in the 
cytoplasm and the proteins are then trafficked to the cell membrane (Fig. 1.1).  
 The Env protein is produced from a spliced variant of the viral mRNA. Env 
contains a hydrophobic signal peptide (SP) within the first ~20 amino acids that 
directs translation of the env to the endoplasmic reticulum (ER) and through the 
secretory pathway (Fig.1.1).  The SP is cleaved off by cellular proteins and in the 
ER the Env is folded and oligomerized; most Envs must be formed into trimers to 
function properly [1].  The Env protein is subsequently exported to the Golgi 
where it is cleaved into its two subunits SU and TM by the cellular enzyme furin, 
which recognizes the motif R/K-X-K/R-R/K.  The two Env subunits can be 
covalently or noncovalently associated depending on the type of virus.  In the 
Golgi, Env proteins are usually heavily glycosylated, most commonly through N-
linked glycosylation. Env is then trafficked to the cell surface, where it is 
anchored into the cell membrane by the membrane spanning domain (MSD) 
located in the TM (Fig. 1.1) [1].  
 Once viral proteins have been expressed and transported to the cell 
membrane, progeny virions will be produced.  The Gag precursor is largely 
responsible for driving particle assembly. Gag proteins assemble at the 
membrane and begin to curve and bud out; they eventually form a sphere that is 
connected to the cell by a narrow stalk that is pinched off [1].  This immature 
virus is spherical and contains the RNA genome and all precursor proteins (Fig. 
1.1).  Alternatively, some retroviruses assemble in the cytoplasm and are 
transported to the membrane to bud out of the cell [1].  As the retrovirus is 
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budding from the cell, the precursor Gag and Gag-Pro-Pol proteins are cleaved 
by the viral protease (PR).  Gag is cleaved into the matrix protein (MA) which 
stays associated with the membrane surrounding the virion, and the capsid 
protein (CA), which forms the viral core (which may be spherical, cylindrical or 
conical depending on the virus type).  The core contains the RNA genome and 
the proteins required for reverse transcription and integration.  Gag cleavage also 
produces the nucleocapsid protein (NC), which is closely associated with the two 
copies of the RNA genome and coats both copies.  NC has additionally been 
shown to be involved with reverse transcription and integration [1].  While Gag is 
cleaved, the Gag-Pro-Pol polyprotein is cleaved into its various products 
including the viral protease (PR), the reverse transcriptase (RT) and integrase 
(IN).  Depending on the type of virus these can form a diverse pattern.  After 
release from the cell and cleavage of the precursor proteins, there is a 
morphological change in the virions where they typically become more compact 
(Fig. 1.1) [1].  Once this morphological change occurs, the mature virion can 
infect a new host cell.  
Classification of Retroviruses  
The Retroviridae are currently grouped into seven distinct genera: 
Alpharetroviruses, Betaretroviruses, Gammaretroviruses, Deltaretroviruses, 
Epsilonretroviruses, Lentiviruses and Spumaviruses, these classifications are 
generally based on their reverse transcriptase gene, core structure and genome  




Alpharetroviruses are simple retroviruses that do not encode accessory 
proteins.  They have a C-type morphology, meaning they assemble at the 
plasma membrane and have a spherical centrally placed core.  During translation 
of the Gag-Pro-Pol polyprotein translational frameshifting is used.  Pro is located 
at the 3’ end of gag and is in the same frame, while pol is in a different reading 
frame. The TM and SU subunits of the Env protein remain covalently associated 
after cleavage.  Alpharetroviruses infect birds; a prototypical alpharetrovirus is 
avian leukosis virus (ALV) that infects chickens and can cause various cancers in 
the avian host [12]. 
Betaretroviruses 
 Betaretroviruses are simple retroviruses that infect mammals including 
mice, sheep and primates.  They have either a B-type morphology with round 
non-centrally placed core or a D-type morphology with a cylindrical core.  Gag, 
pro, and pol are in different reading frames; translational frameshifting is 
used.  Immature betaretroviral particle assemble in the cytoplasm and are 
transported to the cell membrane to bud out of the cell [1].  The two subunits of 
Env, SU and TM, are non-covalently associated [1], [13].  Examples of 
betaretroviruses include mouse mammary tumor virus (MMTV) which causes 
cancerous growth in mammary glands of mice and can be passed to offspring 
through the milk or in an endogenous fashion [14].  MMTV has an additional 
assessor gene called sag, or superantigen, that causes T-cells to be activated 
[1].  Jaagsiekte sheep retrovirus (JSRV) infects sheep and causes lung cancer 
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[15].  Mason-Pfizer monkey virus (MPMV), which is part of a larger group of 
viruses called simian retroviruses (SRV), infects Asian macaques causing 
immune deficiency that can be fatal [16].  Interestingly the MPMV env originated 
from a crossover event and is of gammaretroviral origin [13].    
Gammaretroviruses 
 Gammaretroviruses are simple retroviruses with the largest number of 
known members, potentially due to the wide species tropism observed, infecting 
mammals, reptiles and birds.  They have a C-type morphology assembling at the 
cell surface with a spherical central core. Gag, Pro and Pol are produced through 
translational readthrough with a stop codon at the end of gag. Gammaretroviral 
Env subunits are covalently associated and commonly recognize a 
multimembrane spanning protein as a receptor [1], [13], [17]. Gamma Envs 
commonly require processing in the cytoplasmic tail by the viral protease during 
the maturation stage in order to activate the fusogenic ability of Env (Fig. 1.3) 
[18]–[23].There are numerous examples of gammaretrovirus, three of them are: 
murine leukemia virus (MLV), feline leukemia virus (FeLV) and koala retrovirus 
(KoRV).  MLV can cause cancer in mice, FeLV has many detrimental health 
effects in cats but the final stage is the development of lymphomas, KoRV has 
been implicated in koala immune deficiency syndrome (KIDS) which can lead to 
many health risks for koalas [24]–[26].  All three of these viruses have exogenous 





Deltaretroviruses are complex retroviruses that have several additional 
genes including rex and tax which are involved with the synthesis and processing 
of the viral RNAs. These retroviruses have a C-type morphology assembling at 
the cell surface and have a spherical central core.  They use translational 
frameshifting; the gag, pro, and pol are all in different reading frames [1].  They 
have gamma-type Envs, with SU and TM covalently associated [13].   
Deltaretroviruses are known to infect primates and bovine, examples being 
human T-lymphotropic viruses (HTLVs) and bovine leukemia virus (BLV), they 
can cause leukemia in their host along with other health problems [27], [28].  
Epsilonretroviruses 
 Epsilonretroviruses are complex retroviruses with one to three additional 
open reading frames termed ORFs a, b or c.  They have a C-type morphology. 
Translational readthrough is used in translation with a stop codon at the end of 
gag [1].  their Envs are not well characterized but sequence analysis suggests a 
unique morphology [29]. Epsilonretroviruses are waterborne and infect mainly 
fish.  Two examples are walleye dermal sarcoma virus (WDSV), which causes 
tumors in walleye; and walleye epidermal hyperplasia virus 1 and 2 (WEHV-1 or 
2) which induce a neoplastic condition in fish resulting in lesions [30], [31].   
Lentiviruses 
 Lentiviruses are complex retroviruses that infect a wide variety of 
mammals including primates, cats, horses, cows and rabbits [1].  They can have 
multiple accessory genes specific to the virus, which have numerous functions 
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such as: antagonizing the host innate immune system, controling transcription, 
RNA processing, virion assembly and host gene expression [1]. During infection 
lentiviruses are able to infect dividing and non-dividing cells [6], [10], [11].  The 
capsid core has a unique morphology being either cylindrical or conical.  During 
translation, translational frameshifting is used.  The gag is in its own reading 
frame and the pro-pol is in a different reading frame.  The Env subunits are non-
covalently associated in lentiviruses.  There are many examples of lentiviruses.  
Two examples are: human immunodeficiency virus type 1 (HIV-1), which if left 
untreated it can lead to acquired immune deficiency syndrome (AIDS) [1] and 
equine infectious anemia virus (EIAV), which can cause multiple health 
complications in horses, the main one being anemia [32].      
Spumaviruses 
 Spumaviruses (also known as foamy viruses) are complex retroviruses, 
unique in multiple different ways, including their morphology characterized by 
large surface spikes and an uncondensed core [1], [33].  Virion assembly occurs 
in the cytoplasm and budding takes place either from the ER or the plasma 
membrane. Translation of gag and pol is unique because pol is translated from a 
mRNA splice variant.  At the 3’ end of env there is another transcriptional start 
site [1], [33]. Spumaviruses characteristically form large vacuoles in their host.  
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Figure 1.4: Endogenization of a Retrovirus. Spreading retroviruses infect a 
host by inserting their genome into the host DNA, most commonly into a 
somatic cell.  Production of virus from these somatic cells results in horizontal 
transmission of the virus within a population (top left).  Occasionally, a 
retrovirus will infect a germline cell (purple and red virus), when this occurs the 
proviral DNA can be vertically transmitted to the offspring, somatic cell 
infections cannot be vertically transmitted to the offspring (orange virus).  
When vertical transmission happens, the retrovirus has been endogenized and 
is present in all the somatic and germline cells of the host. Several events can 
happen once a retrovirus is endogenized, perhaps the most common event is 
for the ERV to be lost (purple virus).  If not lost an ERV will be passed on in a 
Mendelian fashion spreading in the population (red virus middle) and 
eventually over millions of years it can become fixed within a population (red 
virus bottom).       
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Endogenous Retroviruses 
The normal mode of spread of an exogenous virus is horizontally from one 
host to another, usually infecting somatic cells (Fig. 1.4).  Occasionally a 
retrovirus will infect a host germline cell and the provirus can then be passed  
vertically to the host’s offspring (Fig. 1.4).  The retroviral provirus is then present 
in every cell of the offspring and is considered endogenized creating a new 
endogenous retrovirus (ERV) (Fig. 1.4).  ERVs are passed on in a Mendelian 
fashion, though, most new ERVs are lost soon after insertion, which could be due 
to it being detrimental to the host or the host lineage being lost (Fig. 
1.4).  Occasionally an ERV will become fixed within a population, which can take 
millions of years (Fig. 1.4).  Once part of the host genome, the ERV provirus is 
subject to the host mutation rate and typically evolves with the host as any other 
gene.  In most cases, the ERV provirus accumulates deactivating mutations such 
that infectious virions can no longer be produced.  Another common occurrence 
is the formation of solo LTRs.  Because LTRs are identical upon integration, 
recombination between the two can occur, which results in loss of the ERV 
proviral genome between the LTRs, leaving one LTR in its place [34]–[36].  
There are a couple of ways to calculate the age of ERVs.  First, because the 
LTRs are identical upon insertion, the number of accumulated mutations between 
the two can be used to estimate the age of the ERV.  By applying the host 
mutation rate and the divergence between the two LTRs an estimated time of 
insertion can be calculated [34], [37]–[41].  Additionally, if an ERV is present at 
the same locus in different species (orthologous insertions), the insertion event 
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must have predated speciation, and by utilizing known speciation timelines the 
ERVs age can be estimated [34],[42].  
Typically, only one copy of a retrovirus enters the germline, but once there 
the copies of the ERV may be expressed and reinserted into the host genome, 
which can lead to an expansion of the ERV within the genome resulting in 
multiple copies [34], [42]. Deactivating mutations seem to be the major form of 
controlling expression of ERVs, however, there is some question of how 
potentially active ERVs are controlled.  The main host method of controlling ERV 
expression appears to be epigenetic, through methylation modification in order to 
deactivate the ERV [34], [42]–[45]. Occasionally, an ERV proviral gene will have 
a maintained open reading frame (ORF). It is currently not known why most of 
these genes have ORFs, although in some instances these ERV ORFs have 
been co-opted by the host for a function (see below).  
ERVs were discovered and characterized in the late 1960s and early 
1970s.  One of the first studied was endogenous ALV; ALV was a problem in 
chickens in the 1960s, to find a solution to the virus a serological test was 
developed to test for ALV Gag.  However, it was discovered that some uninfected 
chickens still tested positive for ALV [46], [47].  It was further shown that the Gag 
antigen that was being detected was inherited in a Mendelian fashion [48], 
[49].  Around the same time, it was observed that some chicken embryo cells 
would release infectious pseudotyped virus without an Env being provided [46], 
[50], [51].  This suggested the possibility of an endogenous env [46], [52], [53].  It 
was observed with inbred chickens, that the env was being inherited in a 
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Mendelian fashion [54].  With the discovery of RT, uninfected chickens were 
tested for proviral ALV DNA.  The test revealed numerous copies of ALV in most 
chicken breeds, many of them defective.  Further tests confirmed the finding and 
identified differences between the endogenous and exogenous retroviruses [8], 
[42], [46], [55]–[59].  While endogenous ALV was being discovered, endogenous 
MLV was also detected.  In 1933, a mouse strain (AKR) was developed that had 
a high probability of developing lymphoma, however the cause was unknown at 
the time [7],[60], [61].  When MLV was classified as a virus in 1951, it was also 
understood to be the causative agent in the formation of lymphomas in AKR mice 
[46], [60].  It was not until the 1970’s that it was discovered it was endogenous 
MLV causing lymphomas in AKR mice.  The same as endogenous ALV, 
uninfected mouse cells were observed to spontaneously release MLV.  It was 
also found that there were numerous copies of endogenous MLV that were 
largely defective [42], [46], [62]–[64]. The discovery of these ERVs opened a new 
line of investigation, and through the use of multiple different methods including 
hybridization and PCR, other ERVs were discovered [65], [66].  However, it was 
not until full genome sequencing that the full extent of ERVs could be 
appreciated. ERVs are widespread throughout vertebrate animals; for example, 
in humans they comprise about 8% of the genome, and other sequenced 
vertebrate genomes show similar numbers across the board [67]–[69].   
While it is easy to think of ERVs as ancient, there are examples of ERVs 
that are polymorphic within populations and that are still in the process of 
endogenizing, meaning they are endogenized but are not fixed.  An example is 
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human ERV-K (HERV-K), which began infecting germlines and endogenizing 
before the split from old world monkeys 25-30 million years ago [2].  However, 
HERV-K appears to have been active fairly recently as evidenced by an insertion 
that seems to be intact and by the fact it is polymorphic within the human 
population [2], [70]–[72].  Another example of an ERV that is still in the process of 
endogenizing is KoRV-A, which is currently spreading both horizontally and 
vertically in koalas [73].    
ERV-Fc Family of ERVs 
The work described in this thesis involves env genes belonging to ERVs of 
the ERV-Fc family. ERV-Fc is a gamma-like endogenous retrovirus that was first 
characterized in the Heidmann lab [74], [75].  During a screen of genomic 
databases using the immunosuppressive domain (ISD) as a query, an ERV Env 
was found in the human genome that did not fit into any known ERV 
families.  Due to its phenylalanine (F) tRNA PBS it was named human ERV-Fc 
(HERV-Fc) [75].  HERV-Fc is scientifically important as it has a maintained env 
ORF, consequently the Heidmann lab looked further into HERV-Fc.  They found 
that in humans there are two different types: HERV-Fc1 and HERV-Fc2.  HERV-
Fc1 has a full provirus, but only the env gene has an ORF.  There are five copies 
of HERV-Fc2 with mostly present proviruses, of the five, one HERV-Fc2Δenv has 
an env ORF.  However, HERV-Fc2Δenv env ORF is truncated before the MSD 
due to a deletion of the 3’ end of the provirus [74].  In addition to humans they 
found ERV-Fc with an intact env ORF in baboons (babERV-Fc2).  Based on LTR 
divergence it was estimated the HERV-Fc2 integrated into the primate genome  
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  Figure 2. The genomes of most Eutherian mammals harbor ERV-Fc. A mammalian phylogeny (adapted from
[(Bininda-Emonds et al., 2007]) including species whose genomes were examined for the presence of ERV-Fc.
Species lacking ERV-Fc are depicted in red, while those found to harbor ERV-Fc are depicted in green. Bold font
indicates that coding potential in one or more gene regions could be reconstructed, italics indicates that ERV-Fc
fragments were identified but coding potential could not be reconstructed; * indicates that only a solo LTR was
identified; and †† indicates that a species harbors two genetically distinct ERV-Fc lineages. Background shading
indicates higher-order taxonomic relationships: blue = Euarchontoglires, pink = Laurasiatheria, green = Xenarthra,
purple = Afrotheria, brown = Metatheria. Envelope icons indicate species in which ERV-Fc env open reading frame
(s) were identified, and the icons colored green indicate env with homology to HERV-Fc; yellow icons indicate the
env had greater similarity to HERV-W. ERV, endogenous retrovirus. HERV, human ERV.
Figure 2 continued on next page
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Figure 1.5: ERV-Fc in 
Eutherian mammal genomes.  
Species that ERV-Fc were not 
found in are in red, species 
with ERV-Fc in their genome 
are in green.  If one or more 
ERV-Fc gene could be 
reconstructed the name is in 
bold, italics indicate fragments 
were identified but they could 
not be reconstructed. * = only 
a solo LTR was found, ✝✝= 
the species has two genetically 
distinct ERV-Fc lineages in is 
genome. Envelope icons 
indicated an env ORF(s) was 
found in that species, green 
ones indicate they are 
classical ERV-Fc envs and 
orange icons indicate the env 
originated from a crossover 
event. (Figure adapted from 
Diehl et al. 2016.)    
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20 to 32 million years ago, and that babERV-Fc2 is a recent integration due to 
the identical LTRs [74].  Heidmann was also able to confirm through polymerase 
chain reaction (PCR) the presence of HERV-Fc1 and two of the HERV-Fc2s at 
the same locus in chimpanzees and gorillas [74].  A large real-time quantitative 
PCR screen of HERV env ORF transcript levels showed low levels of HERV-Fc1 
transcripts in human skin, testis and trachea tissue, and HERV-Fc2Δenv 
transcripts in skin and testis tissue [76].  
Using Basic local alignment search tool nucleotide (BLASTn), we 
previously screened 50 mammalian genomes searching for ERV-Fc loci.  ERV-
Fc loci were found in 28 of those genomes, including previously characterized 
dog ERV-Fcs (cfERV-Fc) (Fig. 1.5) [77], [78].  Additionally, env ORFs were found 
in marmosets, squirrel monkeys, lemurs, aardvarks, pandas and dogs; adding to 
the list of ERV-Fc env ORFs previously discovered in humans, chimpanzees and 
baboons (Fig. 1.5) [77].  By looking at LTR divergence, it was determined that  
ERV-Fc was spreading and infecting a wide host of mammals between ~33 
million to ~15 million years ago [77].  Phylogenetic analysis determined that at 
least 26 cross-species transmission events gave rise to the identified ERV-Fc 
insertions, though as ERV-Fc spread exogenously the number was probably 
greater as the ERV-Fc “fossil” record can only give a narrow picture of how the 
virus actually spread [77].  During the phylogenic analysis, it was also discovered 
that ERV-Fc has experienced several recombination events. At least one 
recombination event has led to an ERV-Fc in carnivores to acquire an env that 
aligned more with HERV-W than ERV-Fc envs (Fig. 1.5).  The recombinant ERV 
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then infected dogs, pandas and ferrets, resulting in the env ORFs in dogs 
(cfERV-Fc1(a)-env) and pandas (ameERV-Fc1-env) (Fig. 1.5) [77].   
Gammaretrovirus Envelope Glycoproteins 
 This thesis describes the reconstitution and functional characterization of 
the Env proteins of the ancient lineage of gammaretrovirus that gave rise to ERV-
Fc elements in mammalian genomes.  Gammaretrovirus Envs have the 
canonical signal peptide at the beginning of their sequence as well as a furin 
cleavage site between the SU and TM (Fig. 1.3).  The gammaretrovirus Env also 
has several distinctive features.  The SU and TM domains are covalently 
associated; a CXXC isomerization motif in the SU and a CX6CC motif in the TM 
are responsible for this interaction (Fig. 1.3).  Additionally, in the TM there is an 
immunosuppressive domain (ISD) directly before the CX6CC motif (Fig. 
1.3).  The fusion peptide in gamma Envs is typically found in TM immediately 
after the furin cleavage site (Fig. 1.3).   
Also, unique to gamma-like Envs is the R-peptide, a short sequence at the 
end of the cytoplasmic tail that is cleaved off by the viral protease after virion 
assembly to activate the Env’s fusogenic ability (Fig. 1.3).  The R-peptide has 
been studied in both MLV and MPMV.   The MLV R-peptide was first discovered 
when two forms of the TM subunit were observed, one with a slightly lower 
molecular weight originally termed p15(E) and p12(E) [18].  Through use of a 
sequence specific antibody the cleavage product was confirmed.  It was also 
found that it (the R-peptide) was cleaved off during the final viral maturation 
stage [19], [20].  Reversed-phase high-pressure liquid chromatography was used 
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to separate MLV protein products and the R-peptide was isolated and 
sequenced.  It was determined that the R-peptide was the last 16 amino acids of 
the TM subunit and the cleavage occurred between a leucine (L) and a valine (V) 
[21].  Expression of truncation mutants of the MLV Env resulted in cell-cell fusion 
when only the R-peptide was missing.  This cell-cell fusion did not occur when 
full length MLV Env was expressed.  This indicated that cleaving the R-peptide 
off the Env activated the fusion ability of the Env [22], [23].   
Similar to MLV, MPMV’s R-peptide was discovered when TM was 
observed to have two different molecular weights.  During a pulse-chase 
experiment it was noted that within the cell the TM was in a gp22 form.  Once the 
virions budded the gp22 form began to decrease while a gp20 band increased 
until it was the major form of TM, indicating about 16 amino acids were being 
cleaved off with a probable cleavage site between a tyrosine (Y) and a histidine 
(H) [79].  Because the cleavage happens in virion and not the host cell, it was 
thought the viral protease must be responsible for the processing.  To confirm the 
hypothesis the viral protease was mutated and a protease inhibitor was used.  
Applying either method the Env was still incorporated into virions; however, 
processing between gp22 and gp20 was impaired as was infection [79], [80].  As 
with MLV, when truncation mutants were made in the MPMV TM cytoplasmic tail 
cell-cell fusion was greatly enhanced [81].  
Further confirmation of R-peptides in gammaretroviral Envs and the effect 
cleaving off the R-peptide has on activating fusion was done with three viruses 
with gamma Envs: gibbon ape leukemia virus (GaLV), spleen necrosis virus 
	 24	
(SNV), and porcine endogenous retrovirus (PERV) [82].  They all have the same 
L-V motif in their cytoplasmic tail as MLV, truncations were made to this site and 
the mutant Envs were expressed in cells.  Cell-cell fusion was observed for the 
truncated Envs [82].  In addition to being important for fusion of the virion to a 
new host cell, the R-peptide may be involved in targeting the Env for 
incorporation into virions.  It was shown with MPMV and MLV that truncating the 
cytoplasmic tail to the R-peptide or introducing mutations in certain areas of the 
R-peptide led to lower levels of Env incorporation into virions [81], [83]. The 
gammaretroviral R-peptide therefore plays a role both in incorporation into virions 
and in the activation of the Env’s fusogenic ability.  
Host Co-option of ERVs (Exaptation) 
 The work in this thesis also reflects the potential evolutionary cooption of 
ERV Env for host functions.  As more ERVs have been discovered with genome 
sequencing, the question of why some have maintained ORFs has been 
investigated, leading to the discovery that multiple ERVs have been exapted by 
the host for a beneficial function.  The function of these ERVs tend to fall into two 
categories: use of the Envs fusogenic ability or use as an anti-viral factor (Fig. 
1.6 and 1.7) [34].  
Syncytins 
 The use of an ERV env for its fusogenic ability is exemplified by the 
syncytin genes.  Syncytins are ERV genes involved in the formation of the 
syncytiotrophoblast layer in the placenta, a multinucleated syncytium (Fig. 1.6) 















Figure 1.6: Formation of a 
syncytium. Depiction of how a 
multinucleated syncytia 
forms, when one cell 
expresses a viral Env, the 
Env can bind a receptor on a 
neighboring cell (top) and 
trigger fusion (middle) 
resulting in the two cells 
fusing together into one cell 
with multiple nuclei (bottom). 
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can be considered a syncytin: first, it needs to be expressed in the placenta; 
second, it must have maintained its cell-cell fusion ability (Fig. 1.6); finally it 
should be highly conserved among related taxa [85].  Through the use of these 
criteria, multiple syncytins have been found in a wide swath of mammals  
including: primates, carnivores, ruminants, rodents, marsupials, tenrecidae and 
leptoridae [86], [87]. Most of these syncytins appear to have emerged 
independently as early as 85 million years ago.  However, the first placental 
mammals emerged roughly 150 million years ago, indicating there may have 
been an original captured ERV Env syncytin that over time has been replaced by 
other ERV Envs in different species [87]. In humans there appear to be two main 
syncytins, a HERV-W env and an HERV-FDR env, known as syncytin-1 and 
syncytin-2, respectively [84], [87]–[89]. Both are highly expressed in the placenta 
cells involved with the formation of the syncytiotrophoblast layer [84], [87], [89]–
[91]. Syncytin-1 is highly conserved in Hominids, having entered the genome 
before the split with Old World monkeys, making it roughly 30 million years old 
[92].  It uses the RD-114 and D-type retrovirus (RDR) supergroup receptor 
ASCT2, a neutral amino acid transporter [90].  Syncytin-2 is conserved in all 
primates except prosimians and is estimated to be 45 million years old [93].  Both 
of these ERV Envs can mediate fusion of cells in culture; silencing of either gene 
leads to an impairment of cell-cell fusion [87], [94]–[98].  In addition to their 
fusogenic ability there is some evidence that Envs have an immunosuppressive 
function because of the ISD [86].  In a tumor rejection assay in mice it was found 
that syncytin-2, but not syncytin-1, is immunosuppressive [99], [100]. This 
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suggests a potential role for syncytins in immunosuppression to help prevent 
fetal rejection by the mother.  
 While it is almost impossible to confirm whether the human syncytins are 
involved in the formation of the placenta, proof of concept was tested in mice.  
After the sequencing of the mouse genome two potential syncytin genes were 
found, syncytin-A and syncytin-B.  Even though the mice syncytins are 
genetically distinct from the human syncytins they have some of the same 
characteristics: they are expressed specifically in the placenta, are fusogenic and 
are highly conserved from when they were endogenized approximately 25 million 
years ago [101].  Similar to their human counterparts, syncytin-B is 
immunosuppressive while syncytin-A is not [100].  To test the actual importance 
of syncytins in pregnancy, knockout mice were created. When syncytin-A was 
knocked out the embryos died at midgestation; there was significant placental 
architectural defects and an accumulation of unfused cells [102].  When syncytin-
B was knocked out the phenotype was not as severe, the animals were still 
viable, but there was growth retardation and fewer offspring [103]. A double 
knockout of both syncytin genes demonstrated a more severe phenotype than 
the syncytin-A knockout with the embryos dying earlier than in the single 
knockout, indicating that both syncytins are required for proper placenta 
formation [103].   
ERVs coopted for an Antiviral function  
 In addition to ERVs being coopted for their fusogenic ability they have 






















Figure 1.7: Antiviral ERVs. Representation of where ERV proteins act as 
antiviral agents.  Fv1 acts early in the viral life cycle before integration 
potentially binding to the viral capsid.  Fv4, rmfc1, rmfc2, ev3, ev6, ev9 and 
Refrex-1 are all ERV Envs that use receptor interference, blocking the 
receptors from use by an exogenous virus.  This may occur in the ER at the 
cell surface or in the case of Refrex-1 in the extracellular space after being 
secreted.  The virus these factors block are in parentheses bellow the factor 
(red boxes).    
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discovered was friend virus susceptibility factor 1 (Fv1) in mice, which protects 
mice from infection by exogenous MLV (Fig. 1.7).  First characterized in the 
1970s it was not originally known to be of ERV origin, but it was observed that 
mice with the Fv-1 locus were resistant to MLV [104].  There are two different loci 
of Fv-1 that lead to the identification of three variants of MLV.  Fv-1n found in 
NIH/Swiss mice confers resistance to N-tropic MLV, Fv-1b found in Balb/c mice 
confers resistance to B-tropic MLV, but not visa-versa.  Heterozygous Fv-1n/Fv-
1b mice are resistant to both N- and B-tropic MLV.  Additionally, there is a NB- 
tropic MLV that can avoid being blocked by either locus of Fv-1 [104]–[106].  It 
was not until the 1990s when the Fv-1 locus was cloned that it was discovered 
that it encodes a Gag-like protein similar to the endogenous families HERV-L and 
murine ERV-L (MuERV-L) [107] .  Recent studies have found orthologous Fv-1 in 
rodents, outside of just mice, suggesting an endogenization event at least 45 
million years ago [108].  Cells stably expressing Fv-1 and challenged with EIAV 
and feline foamy virus (FFV) showed a reduced infection rate, indicating Fv-1 
have the potential to protect against a wide range of viruses [109].  The 
mechanism of Fv-1 restriction is not clear, but it is known that it acts early in the 
viral life cycle before integration, and it is thought to bind to the entering capsid 
core, similar to TRIM5a, but how infection is prevented from continuing is not 
known (Fig. 1.7) [105], [110]–[112].     
 Receptor interference is another antiviral method that ERVs have been 
coopted for, which involves the env gene (Fig. 1.7). When expressed they may 
bind to a receptor blocking use by another viral Env, consequently protecting that 
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host from infection from an exogenous virus that uses the same receptor (Fig. 
1.7).  There are multiple recorded instances of this occurring: in mice, there is 
friend virus susceptibility factor 4 (Fv-4), rmfc1 and rmfc2, in chickens 
endogenous ALVs ev3, ev6 and ev9, and in cats Refrex-1 (Fig. 1.7) [113]–[117].    
 The first ERV Envs discovered to conferred receptor interference were 
endogenous ALVs.  ALV has several subgroups based on their Envs: A, B, C, D 
and E. Subgroup E originates from recombination events with endogenous ALV, 
which can then infect and spread in a chicken population [113].  It was observed 
after doing crosses of chickens, that some chickens had low susceptibility to 
infection by ALV-E, but were susceptible to ALV-B and C [113].  When the 
endogenous viral loci were observed, it was found that chickens with ev3, ev6 
and ev9 loci were resistant to ALV-E and chickens that did not have these loci 
were susceptible to infection by ALV-E. Chickens with only ev3 were 
intermediately protected and those with ev6 and ev9 were highly protected.  
Cultured cells expressing these Envs were also able to protect against infection 
[113].  This suggests that ev3, ev6 and ev9 have been evolutionarily maintained 
to protect chickens from the horizontal spread of ALV-E, and the likely mode of 
protection is by blocking the receptor analogous to receptor interference (Fig. 
1.7). 
 Fv-4 was thought to be a gene in mice that made them resistant to Friend-
MLV (F-MLV) or ecotropic MLV [115].  An Asian mouse, strain G, was found to 
be resistant to N- B- and NB-MLV indicating a different restriction factor than Fv-
1, it was also identified in a wild mouse population in southern California around 
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Lake Casitas  [115], [118]–[120].  During the investigation into Fv-4 it was 
discovered that it resembled a MLV Env and presumably acted through receptor 
interference (Fig. 1.7) [121], [122].  An env specific probe was used to identify 
Fv-4s sequence and to confirm it was similar to exogenous MLV env [123].  
When fully sequenced it was found that Fv-4 is part of a defective provirus, with 
the only remaining pieces belonging to the 3’ end of pol, the full env and the 3’ 
LTR [124].  While the Fv-4 is able to block the F-MLV receptor it is incapable of 
infecting cells, when virus was pseudotyped with full length Fv-4 it was 
noninfectious [125].  The defect in ability of Fv-4 to mediate entry was later 
mapped to the fusion peptide, where there is an arginine (R) in place of a highly-
conserved glycine (G), this point mutant reduced the ability of Fv-4 to mediate 
fusion [126].  Fusion, therefore, is not a necessary function for Envs to confer 
receptor interference.  
 In mice, there are two other ERV envs that confer resistance to 
exogenous virus, they are rmfc1 and rmfc2.  Rmfc1 was first discovered in 1983, 
when it was observed that DBA/2 mice were resistant to several forms of MLV 
including a recombinant MLV called mink cell focus-forming (MFC) virus. The 
resistance was found to be separate from Fv-1 restriction and thought to involve 
restriction of the incoming Env [116].  Using type-specific antibodies it was 
confirmed that rmfc was an endogenous ERV env gene, and it restricts through 
receptor interface [127].  This was later proved when the full length provirus was 
found after doing mouse crosses with mice without rmfc1; only the env of the 
provirus was intact, the gag and pol genes were defective due to deletions [128].  
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Rmfc2 blocks infection by polytrophic MLV.  Through genetic crosses rmfc2 was 
discovered to be an ERV env and was associated with a full provirus that had a 
large deletion in integrase [117], [129].  In mice, this brings the total of ERV env 
antiviral genes up to three; all are distinctly different from each other but act in a 
similar manner (Fig. 1.7).  
 There are several endogenous retroviruses in cats; one of the families is 
endogenous gammaretrovirus of domestic cats (ERV-DCs).  There are at least 
19 insertions of the  ERV lineage in cats [130].  These ERVs are polymorphic 
(not fixed) except ERV-DC7 and ERV-DC16. LTR divergence of ERV-DC7 
indicates it was endogenized 2.8 million years ago.  ERV-DC10 and EV-DC18 
are completely intact and can still make replication-competent virus that has a 
broad infectious tropism [130].  A recombination event between FeLV and ERV-
DC envs resulted in a new subgroup, FeLV-D, though it is not clear whether this 
is currently a spreading virus capable of producing infectious virus [130].  While 
determining the receptor interference groups of FeLV-D and the ERV-DCs, it was 
discovered that the supernatant from feline 3201 cells blocked infection from 
FeLV-D and genotype I ERV-DCs.  The phenotype was additionally observed 
with supernatant from other cat cells, but not other species such as human or 
dog [114].  It was hypothesized that there was a secreted restriction factor in 
supernatant from cat cells, later named restriction for feline retrovirus X (Refrex-
1).  cDNA produced from 3201cells mRNA indicated that Refrex-1 came from two 
loci, the ERV-DC7 and ERV-DC16 envs [114].  Both of these Envs have an early 
stop codon truncating them in the SU after the hypothetical receptor binding 
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domain.  They are expressed in cat tissues and supernatant from cells 
transfected with ERV-DC7 or ERV-DC16 inhibit infect by FeLV-D, indicating that 
Refrex-1 is expressed from both of the loci [114].  Refrex-1 acts through receptor 
interference, likely after it has been secreted from the cell, and may have been 
maintained to protect against the reemergence of ERV-DCs, contributing to their 
endogenization (Fig. 1.7)  [114].  Interestingly even when the full length ancestral 
Refrex-1 was reconstructed furin was unable to cleave the env into the SU and 
TM subunits, this defect was due to a mutation upstream of the furin cleavage 
site [131].  The mutation and the early stop may have contributed to ERV-DC7 
and ERV-DC16s exaptation and use as an antiviral factor.   
 Recently a study was done on HERV-T that suggests it might have had an 
antiviral function.  HERV-T entered the primate germline ~43 to 32 million years 
ago with the most recent fixed integrations occurring about 11 million years ago 
[132]–[134].  A reconstructed ancestral HERV-T env (ancHTenv) was able to 
infect a wide range of mammalian cells and was found to use human 
monocarboxylate transporter 1 (hMCT1) as a receptor [134].  Interestingly the 
human genome has a copy of HERV-T with an almost complete env ORF, 
lacking only five amino acids from the C-terminus [76].  Similar to Refrex-1 and 
Fv-4 this HERV-T Env (hsaHTenv) is defective in several ways [114], [125], 
[126], [131].  The HERV-T Env is not correctly processed and or incorporated 
into virions, therefore, it is non-infectious [134].  This is due in part to mutations in 
the furin cleavage site; however, comparable to Refrex-1 when the cleavage site 
was reconstructed, furin cleavage was not restored, indicating there may be 
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additional deactivating mutations [131], [134].  Even with these defects, when 
hsaHTenv was expressed in cells with the receptor and then challenged with 
virus containing ancHTenv it was able to block infection, acting in an antiviral 
fashion.  It appears to achieve this block by reducing the amount of hMCT1 at the 
cell surface, as seen in a depletion of hMCT1 in western blots and tagged 
hMCT1 from cell surfaces [134].  The hsaHTenv provirus was inserted into the 
germline around 13 to 19 million years ago, and during that time has been under 
selective pressure to maintain the env ORF [134].  All of these combined suggest 
that hsaHTenv was preserved for an antiviral function and may have contributed 
to the elimination of the exogenous form of HERV-T [134].   
 This thesis describes functional characterization of the env ORFs of the 
ERV-Fc family.  We hypothesize that these ORFs have been maintained for a 
cellular function, similar to Fv-4, rmfc-1 and rmfc-2 in mice.  Functional 
characterizations of the Envs provides insight into exaptation of ERVs and a 



























Codon optimized sequences for expression in human cells of: human, 
chimpanzee, bonobo and gorilla-Fc1 consensus (conERV-Fc1), human-Fc2Δenv 
(HERV-Fc2Δenv), baboon-Fc2 (babERV-Fc2), marmoset-Fc3-1 (cjaERV-Fc3-1), 
squirrel monkey-Fc3-1 (sboERV-Fc3-1), grey mouse lemur #1 (gmlERV-Fc-#1), 
grey mouse lemur #2 (gmlERV-Fc-#2), aardvark-Fc1 (oafERV-Fc1), dog-Fc1(a) 
(cfERV-Fc1(a)) and panda-Fc1 (ameERV-Fc1) were synthesized (GenArt-
Thermo Fisher Scientific).  Sequences were then cloned into pcDNA3.1+ using 
the restriction enzymes EcoRI-HF and NheI-HF (NEB). A non-codon optimized 
sequence of babERV-Fc2 was also synthesized and cloned into 
pcDNA3.1+.  Codon optimized sequence of HERV-FcΔenv with a membrane 
spanning domain and the MLV cytoplasmic tail (HERV-Fc2Δenv-MLVct) were 
synthesized and cloned into pcDNA3.1+.  All synthesized sequences contain a c-
terminal Avi tag.  
Around-the-horn PCR was used to modify the furin cleavage site of 
babERV-Fc2, HERV-Fc2Δenv and conERV-Fc1 (Table 2.1) [135].  Primers were 
generated to flank the site of interest, resulting in babERV-Fc2-cl (IQKQ to 
RQKR), HERV-Fc2Δenv-MLVct-babSP-cl (KSKR to RQKR), conERV-Fc1-
375+ASQLS, conERV-Fc1-H340T, conERV-Fc1-F335G, conERV-Fc1-F335G, 
375+ASQLS, conERV-Fc1-375+ASQLS, P387L, conERV-Fc1-F335G, P387L 
and conERV-Fc1-P387L.  PCR reactions were then digested with DpnI (NEB) for 
1.5 hours at 37°C and then ligated back together using the Promega T4 rapid 
ligase. Cytoplasmic tail truncation mutants of babERV-Fc2-cl were constructed  
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Primer Name Primer 
ERV-Fc-F AAGCTGGCTAGCGCCACCATG
ERV-Fc-R CTCTCTGAATTCTCATTCGTGCCACTC
Bab-ERV-Fc CS F CGCCAGAAACGGGCCGTGTTCCTGCCTCTG  





































Fc1 P to L F TGCCTCTCGTGATCGGCGTG  
Fc1 P to L R GGAACACGGCTCTTTTCTGCC
Fc1 5AA gap F GCCTCCCAGCTGAGCAATCCCCCCATGCGGC
Fc1 5AA gap R CACGAGGGAGGACAGCTCG
Fc1 F to G F GGCACCCTGACCAAGCACCTG 
Fc1 F to G R ATTGCACCAGAAGTATCCGCC
Fc1 H to T F ACCCTGAACATCAGCAGCAACAATAC 
Fc1 H to T R CTTGGTCAGGGTGAAATTGCAC
 
  Table 2.1: Primers used to make constructs.  
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using PCR and primers flanking the desired sequence, reverse primers 
contained the Avi tag (Table 2.1).  Four truncation mutants were made: babERV-
Fc2-cl-Δ4AA, babERV-Fc2-cl-Δ12AA, babERV-Fc2-cl-Δ22AA and babERV-Fc2-
cl-Δ29AA.  All PCR products were gel purified and cloned into pcDNA3.1+ using 
the restriction enzymes EcoRI-HF and NheI-HF. 
Chimeric env’s containing the MLV cytoplasmic tail (MLVct), the babERV-
Fc2 signal peptide (babSP) or the conERV-Fc1 signal peptide (Fc1SP) were 
constructed using PCR and primers that flanked the desired sequence and 
contained either the MLVct+Avi tag or the signal peptides (Table 2.1).  Chimeras 
generated were: babERV-Fc2-cl-MLVct, gmlERV-Fc-#2-MLVct, oafERV-Fc1-
MLVct, cfERV-Fc1(a)-MLVct, HERV-Fc2Δenv-babSP, HERV-Fc2Δenv-
babSPintr, HERV-Fc2Δenv-MLVct-babSP, HERV-Fc2Δenv-MLVct-babSPintr, 
and HERV-Fc2Δenv-MLVct-Fc1SP. All PCR products were gel purified and 
cloned into pcDNA3.1+ using the restriction enzymes EcoRI-HF and NheI-HF.  
Cell lines and cell culture 
 Cell lines were obtained from the American Type Culture Collection 
(ATCC).  Cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM): HEK293T/17, MDCK, Hos, LLC-MK2, CRFK, DF-1, or Eagle’s 
Minimum Essential Medium (EMEM): HT1080, Vero or F-12 medium, A549. 
Media was supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine 
(200mM), 1% Penicillin-Streptomycin (10,000 IU- 10,000 µg/ml) and 2.5% 
HEPES (1M).  Cells were incubated at 37°C except DF-1, which were incubated 
at 39°C.  
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Western blots  
 293T/17 cells seeded in 6-well plates were transfected with 1μg of 
plasmids containing the ERV-Fc-envs using GenJet (SignaGen).  48 hours after 
transfection cell lysates were collected by directly lysing cell in the wells with IP 
lysis buffer (50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 1% Triton x-100, 5% 
glycerol, pH 7.5).  Lysed cells were centrifuged at 4°C and 14,000 rpm and the 
supernatant was saved.  Supernatants were then boiled with 2X laemmli buffer 
and loaded onto a 12% SDS-PAGE gel for electrophoresis. Proteins were 
transferred to a PVDF membrane, the membrane was blocked with 1X-PBS-
Tween80-5% milk.  Membranes were then probed with monoclonal mouse anti-
Avi (Avidity) then goat anti-mouse-HRP conjugated antibody (Thermo Scientific). 
Blots were developed with Amersham ECL Select Western Blotting Detection 
Reagent (GE Healthcare) and detected using a ChemiDoc MP imaging system 
(Biorad). Blots were then striped with Restor™ Western Blot Striping Buffer 
(Thermo Scientific), re-blocked with 5% milk then probed with anti-βactin-HRP 
and imaged again.   
Pseudotyping and Infectivity  
 MLV particles were pseudotyped by transfecting 293T/17 cells with pLXIN-
GFP, pCIGB and a plasmid encoding one of the following glycoproteins: 
vesicular stomatitis virus glycoprotein (VSVG), babERV-Fc2-cl-MLVct, gmlERV-
Fc-#2-MLVct, oafERV-Fc1-MLVct, cfERV-Fc1(a)-MLVct.  The plasmids were 
transfected at a ratio of 3:2:1 respectively using GenJet (SignaGenÒ 
Laboratories), total DNA: 2µg (6 well plates), 4µg (T25s) or 8µg (T75s).  MPMV 
	 40	
particles were pseudotyped by transfecting 293T/17 cells with pSARM4 and 
pTMO at a ratio of 1:1 using GenJet, and the same DNA totals listed above.   
48 hours after transfection supernatant was centrifuged at 5000rmp for 5 
minutes and either added directly to cells for infection or viral particles were 
concentrated using Centriprep® 50k filter devices (Merck Millipore).  12 well 
plates of cells at ~50% confluence were used for infection, cells infected include: 
293T/17, Hos, HT1080, A549, Vero, LLC-MK2, CRFK, MDCK, and Df-1.  250μl 
of supernatant containing MLV-NoEnv and MLV-VSVG pseudotyped particles 
was added to cells, 900μl of supernatant of other pseudotyped particles was 
added to cells for infection.  4 hours after infection 500μl of fresh D10 was added 
to cells.  48 to 96 hours after infection, cells were imaged using an EVOS 
microscope then harvested for flow cytometry.  
Superinfection Interference assay   
 293T/17 cells were seeded in 12 well plates for a confluence of ~40%, 
then were transfected with 750ng of: pcDNA3.1+ empty vector, VSVG, 
SIVgp160, conERV-Fc1, HERV-Fc2Δenv, HERV-Fc2Δenv-MLVct-babSP, 
babERV-Fc2, babERV-Fc2-cl-MLVct, cjaERV-Fc3-1, oafERV-Fc1, gmlERV-Fc-
#2 or sboERV-Fc3-1 after 24 hours.  Pseudotyped MLV virus was generated as 
before, with either no Env, VSVG or babERV-Fc2-cl-MLVct for Envs. 48 hours 
after transfection, viral containing supernatant was collected and used to 
challenge cells transfected with Envs, amounts of viral supernatant used were 
the same as above. 48 hours after infection cells were imaged using an EVOS 
microscope then harvested for flow cytometry.   
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Flow/FACS 
 Cells harvested for flow were fixed with 2% paraformaldehyde in 1xPBS. 
The number of GFP positive cells were counted by FACS using BD FACSAria 
cell sorter (BD Biosciences).  The data was analyzed with FlowJo (version 8.7.3, 
FlowJo LLC), % of GFP positive cells was calculated after gating on live cells.  
Bioinformatics and Phylogenetics 
 For BLAST searches, we used NCBI BLASTn and BLASTp functions. All 
sequence alignments and annotations were done in Geneious (version 11.0.5 or 
earlier, https://www.geneious.com), using the multiple alignment tool and 
annotation features [136].  Phylogenetic and sequence diversity analysis were 
also conducted using the Geneious tree builder tool (neighbor-joining) and the 
distances tool after constructing an alignment.  To identify putative signal 
peptides in ERV-Fc Envs, we used the predicted amino acid sequences and the 





















Chapter 3: Results 
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ERV-Fc env ORF proviruses are disrupted  
 ERV-Fc-env ORFs in the human and baboon genomes were previously 
described by the Heidmann lab [74], [75]. Both HERV-Fc1 and babERV-Fc2 are 
full-length proviruses with 5’-3’ LTR identities of 92.8% and 100% respectively.  
HERV-FcΔenv is truncated just upstream of the membrane spanning domain 
(MSD) in env and is missing the 5’ LTR (Fig. 3.1) [74].  More recently, we 
performed an extensive survey of 50 mammalian genomes and discovered ERV-
Fc env with intact ORFs in the genomes of chimpanzee (homERV-Fc1), bonobo 
(ppaERV-Fc1), marmoset (cjaERV-Fc3-1), squirrel monkey (sboERV-Fc3-1), 
grey mouse lemur (gmlERV-Fc-#1 and gmlERV-Fc-#2), aardvark (oafERV-Fc1), 
dog (cfERV-Fc1(a)) and panda (ameERV-Fc1).  Phylogenetic analysis revealed 
that the panda and dog envs originated from a recombination event, while the 
afore mentioned are “classical” ERV-Fc envs (Fig. 3.1) [77].   
 To reconstruct the proviral sequences in which the newly discovered ERV-
Fc env ORFs are found, I used BLAST and extracted flanking sequences 10kb 
upstream and 10kb downstream of each env gene, and analyzed these for 
presence of viral sequences and ORFs related to gag, pro and pol genes of 
retroviruses. I found that none of the proviruses have maintained intact gag or pol 
ORFs, although remnants of the genes were present (Fig. 3.1). The chimpanzee 
and bonobo full-length proviruses are at the same locus as HERV-Fc1 (i.e. these 
are othologous loci).  The HERV-Fc1 provirus is also present in gorillas, but 
contains an early stop codon in the env gene ORF.  The other full length 
proviruses include gmlERV-Fc-#1 and cfERV-Fc1(a).  Genome sequence 
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Figure 3.1: Schematic representation of ERV-Fc proviruses with env ORFs. 
Position of gag, pol, env and LTRs within the provirus is indicated above or 
below the element, ORF envs are shaded medium gray (classical ERV-Fc 
env) or light green (recombinant env).  Green line=frame shift, red line=early 
stop, ??=unknown, NNN=N’s in sequence, Purple line=insertion, Δ=deletion.  
On the left species are listed that the provirus is found in and its specific 
name.  The right lists the accession number, chromosome or contig position 


















































































































































































































































































































































































































































































































































































































































































































































































































































































 ambiguities prevented determining whether the cjaERV-Fc3-1, oafERV-Fc1 and 
ameERV-Fc1 Env ORFs are found in full-length proviruses (Fig. 3.1). In sboERV-
Fc3-1 there is a large deletion of the 5’ end of the provirus including the 5’-LTR 
and part of gag.  I could not determine whether sboERV-Fc3-1 has an ORF in pol 
due to sequence ambiguities in the squirrel monkey genome assembly. There is 
a large deletion between gag and pol in gmlERV-Fc-#2 (Fig. 3.1).   Besides the 
above mentioned proviral defects, all ERV-Fc gag and pol genes had either 
premature stop codons (red lines), frameshift mutations (green lines) or deletions 
(orange lines).  The 5’-3’ LTR identities ranged from 83.7% (gmlERV-Fc-#2) to 
100% (babERV-Fc2) (Fig. 3.1).  
The ERV-Fc Envs from different species have low identity in the SU domain 
 An alignment was made to gain further insight into ERV-Fc Envs (Fig. 
3.2).  The predicted ERV-Fc Env proteins have motifs and features typical of 
exogenous gammaretroviruses (Fig. 3.2 and 3.3A). They code for a surface (SU) 
subunit and a transmembrane (TM) subunit.  Within SU, a signal peptide (SP) is 
predicted for all the sequences except HERV-FcΔenv; there are between 5 and 
12 predicted glycosylation sites and a conserved CXXC isomerization domain 
(Fig. 3.3A).  In TM, there is a predicted fusion peptide immediately after the furin 
cleavage site, a conserved immunosuppressive domain (ISD), a CX6CC domain, 
and a membrane spanning domain (MSD) (Fig. 3.3A). The predicted amino acid 
sequences have a range of identity between 18.8% and 70.5% and a similarity 
between 35.15% and 76.53% (Fig. 3.3A and B).  cfERV-Fc1(a) and ameERV-fc1 







Figure 3.2: Alignment of the ERV-Fc Envs.  Alignment made in Geneious 




Figure 3.3: Conservation of the ERV-Fc Envs is low in the SU domain and 
higher in the TM domain.  (A) Conserved features of the ERV-Fc Envs, 
including the SU (light gray) and TM (dark gray) domains.  Within the SU is 
the signal peptide (SP), the CXXC isomerization domain, and six predicted N-
glycan sites, indicated by a Y, that are conserved in at least five of the 
sequences.  Separating the TM and SU is the furin cleavage site.  In the TM 
positions of the fusion peptide (FP), immunosuppressive domain (ISD), 
CX6CC motif, and the membrane spanning domain (MSD) are indicated.  
There is also one N-glycan site that is conserved in the Envs.  Above is a 
graph representing the average pairwise percent amino acid identity of the 
Envs. Green indicates 100% identity, yellow 30%>100% identity, red shows 
>30% identity. Height of the graph at each position indicates the fraction of 
amino acids that are identical at that position.  Blanks illustrate where there is 
only one sequence in the alignment at that position. (B) Tables with the 
pairwise percent amino acid similarity (Blosum62 with threshold 1) of the full 
length Envs, the SU domain of the Envs and the TM domain of the Envs.  
Lighter green indicates less similarity and darker green indicates higher 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































identity in comparison to the rest of the ERV-Fc Envs due to a recombination 
event that replaced a portion of SU with a heterologous SU sequence (Fig. 3.1 
and Fig. 3.3A and B) [77].  Across retrovirus families, the SU subunit is typically 
less conserved than is the TM subunit. This is consistent with our findings, for 
which the range is 8.4% to 64.7% (identity) and 22.49% to 71.29% (similarity) in 
SU, and 35.6% to 82.6% (identity) and 54.29% to 91.28% (similarity) in TM (Fig. 
3.2 and 3.3A and B).  
Intact ERV-Fc Envs are defective for fusion and entry 
 We next assessed expression and functionality of ten ERV-Fc Env 
proteins by western blot (Fig. 3.4A).  Protein was detected for all constructs in 
varying amounts; three had consistently very low levels of protein expression 
(HERV-FcΔenv, gmlERV-Fc-#1 and ameERV-Fc1), and conERV-Fc1 (a 
consensus between the human, chimpanzee, bonobo and gorilla sequences) 
was expressed at the highest levels (Fig. 3.4A and B).  Processing by furin 
cleavage between the SU and TM was not observed for most of the Envs. While 
this was expected for HERV-Fc2Δenv, babERV-Fc2 and ameERV-Fc1, which do 
not have intact furin cleavage sites, it was unexpected for several of the others, 
which retain intact furin target motifs (Fig. 3.4A and C).  Even with intact furin 
target sites, no processing was observed for cjaERV-Fc3-1 and sboERV-Fc3-1, 
and little to none for conERV-Fc1. Only gmlERV-Fc-#2, oafERV-Fc1 and cfERV-
Fc1(a) were processed between SU and TM with any efficiency (Fig. 3.4A and 






































































































































Figure 3.4: All ERV-Fc Envs are expressed but not fully 
processed.  (A) Western blot analyses of cell lysate from 293T/17 
cells transfected with expression plasmids containing the codon 
optimized Avi tagged ERV-Fc env ORFs.  (B) Re-run western blot 
with more protein for low expressing ERV-Fc Envs HERV-
Fc2Δenv and ameERV-Fc1. (C) Alignment of ERV-Fc Envs furin 
cleavage sites.  Green=canonical/intact cleavage site, 
Red=mutated cleavage site.   
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preserved in the ERV-Fc Envs. Furin cleavage defects would also inhibit ability to 
drive membrane fusion and viral entry into a host cell.  
Restoration of a signal peptide to HERV-Fc2Δenv leads to glycosylation  
HERV-FcΔenv is expressed, but gives a band smaller than the predicted 
size (Fig. 3.4 A and B).  With 13 possible N-linked glycosylation sites, the 
expected observed size is ~85.5kD; the observed size of ~60.4kD is close to the 
predicted size in the absence of glycosylation (Fig.3A and B).  A possible 
explanation for the discrepancy is that HERV-FcΔenv is not trafficking through 
the secretory pathway, which prevents the Env from being glycosylated.  To 
investigate this possibility, we first checked for the presence of a signal peptide in 
the predicted HERV-FcΔenv ORF.  Examination of the conERV-Fc1, babERV-
Fc2 and HERV-FcΔenv sequence by the SignalIP 4.1 server indicates that 
conERV-Fc1 has a predicted signal peptide and cleavage site between positions 
22 and 23, and babERV-Fc2 has a signal peptide and predicted cleavage site 
between position 28 and 29.  HERV-FcΔenv, however, is not predicted to have a 
signal peptide (Fig. 3.5 A, B and C) [137].  To test this possibility, we added two 
different heterologous signal peptides to the HERV-Fc2Δenv construct, based on 
the predicted SPs of babERV-Fc2 and conERV-Fc.  When the chimeric 
constructs were tested by transfection and western blot, the observed proteins 
ran at ~85.5kD, consistent with glycosylation and trafficking through the secretory 







































Figure 3.5: HERV-Fc2Δenv does not have a signal peptide, adding the 
conERV-Fc1 or babERV-fc2 signal peptide to HERV-Fc2Δenv leads to 
glycosylation. (A) babERV-Fc2 predicted signal peptide (B) conERV-Fc1 
predicted signal peptide (C) HERV-Fc2Δenv predicted signal peptide. C-
score (red) is a prediction of where the signal peptide cleavage site is. S-
score (green) is the signal peptide score, predicts the location of the entire 
signal peptide. Y-score (blue) combined cleavage site score, combines the 
C and S score to more accurately predict where the signal peptide 
cleavage site is placed. The higher the score the higher the probability of a 
signal peptide and cleavage site. Data generated using SignalIP 4.1 server 
[137].  (D) Western blot analyses of cell lysate (CL) and supernatant (Sup) 
from 293T/17 cells transfected with expression plasmids containing the 
HERV-Fc2Δenv signal peptide chimeric constructs.  
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Reconstruction of the furin cleavage site does not rescue SU-TM cleavage 
of HERV-Fc2Δenv 
Reconstruction of the HERV-Fc2Δenv furin cleavage site had no effect on 
processing of TM and SU (Fig. 3.6B). Examination of the predicted amino-acid 
sequence revealed a putative N-linked glycosylation motif that overlaps the 
predicted furin-cleavage site and that is not found in other ERV-Fc Env, 
suggesting post-translation glycosylation could be interfering with processing 
(Fig. 3.6A). To test this possibility, a construct with the babERV-Fc2 env SP and 
a reconstructed furin cleavage site (modified to remove the N-glycosylation site) 
was made (Fig. 3.6A).  However, elimination of the N-linked glycosylation site at 
the furin cleavage site (NKSKR to NRQKR) did not result in detectable cleavage 
of the precursor protein, indicating there may be other changes outside of the 
motif that affect recognition or the cleavage by furin protease (Fig. 3.6B).   
Distal mutants fail to restore furin cleavage of conERV-Fc1  
Even though conERV-Fc1 has a canonical furin cleavage site, minimal 
processing is observed, similar to reports of reconstructed Refrex-1 (Fig. 3A) 
[131].  Multiple mutational strategies were attempted to improve cleavage.  When 
the ERV-Fc Envs furin cleavage sites were aligned along with the two 
reconstructed Refrex-1s, several major differences were found (Fig. 3.7A) [131].  
At residue 387 in conERV-Fc, immediately downstream of the cleavage site, 
there is a proline (P) in place of a highly-conserved leucine (L) (Fig. 3.7A).  
Immediately upstream of the cleavage site, babERV-Fc2 Env has 5 extra amino 
























































Figure 3.6: Removing the N-glycosylation site in HERV-
Fc2Δenv does not restore furin cleavage. (A) Alignment of 
HERV-Fc2Δenvs furin cleavage site, purple = N-glycosylation 
site, red = residues changed to remove glycosylation site. (B) 
Western blot analysis of cell lysate harvested from 293T/17 





























































































































Figure 3.7: Cleavage mutants do not restore furin cleavage to 
conERV-Fc1. (A) Alignment of non-recombinant ERV-Fc, ERV-DC7 
and ERV-DC16 Envs furin cleavage site and surrounding sequence.  
Furin cleavage site in green, changes made in ERV-DC7 and ERV-
DC16 to restore furin cleavage (Ito et al. 2016).  Residues changed 
in conERV-Fc1 to attempt to restore furin cleavage are highlighted 
in red.  (B) Western blot analysis of lysate of 293T/17 cells 
transfected with conERV-Fc1 furin cleavage mutants, all constructs 
are Avi tagged.     
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furin cleavage site, shown to be important for Refrex-1 cleavage [131], there are 
two sites of interest in conERV-Fc1.  At site 335 in conERV-Fc1, there is a 
hydrophobic phenylalanine (F), which in the other Envs is a neutral site, most 
commonly a glycine (G) (Fig. 3.7A).  Finally, at site 340 there is histidine (H) in 
conERV-Fc1 Env, again very different from the conserved cysteine (C) or 
threonine (T) found at that location in the ERV-Fc Envs (Fig. 3.7A).  We therefor 
replaced these elements in various combinations and tested the modified 
constructs for expression and processing by transfection and western blot (Fig. 
3.7A and B).   However, no significant improvement in furin cleavage was 
observed compared to the parental construct (Fig. 3.7B).  
Reconstruction of babERV-Fc2 Env restores processing and infection 
capability  
The babERV-Fc2 is the youngest of the ERV-Fc proviruses with an intact 
env ORF, estimated at £1 million years old [74].  Env expression is detectable by 
transient transfection, but the resulting protein is not cleaved into separate SU 
and TM domains (Fig. 3.4A). The native sequence lacks a canonical furin 
cleavage site, most likely due to mutations acquired subsequent to 
endogenization (Fig. 3.4C and 3.8).  To test this possibility, the furin cleavage 
site was first repaired through site directed mutagenesis (IQKQ to RQKR) to 
produce babERV-Fc2-cl (where cl indicates the modification to contain a 
canonical furin-cleavage motif) (Fig. 3.8).  This change in babERV-Fc2-cl 





































Figure 3.8: Reconstructed babERV-Fc2 furin 
cleavage site is functional. Western blot 
analysis of babERV-Fc2 and babERV-Fc2-cl (⍺-
Avi). To the right is a schematic of what portion 
of the Env is seen on the blot: top-full length 
Env, bottom-TM subunit.  Under the full length 
Env is the babERV-Fc2 furin cleavage site, with 
an arrow pointing at the reconstructed cleavage 
site in babERV-Fc2-cl, red amino acids are the 
ones that were changed.   
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appearance of a band corresponding to the Avi-tagged TM subunit on western 
blots (Fig. 3.8).   
I next asked whether the modified babERV-Fc2-cl protein was functional. 
To determine functionality, MLV viral particles were pseudotyped with babERV-
Fc2-cl and used to infect 293T/17 cells.  Little to no infection was seen (Fig. 
3.10), indicating that the Env was not functional, or that the cells do not express 
the receptor.  However, the Env proteins of many gammaretroviruses are known 
to have a C-terminal R-peptide [18], [79], [82].  The presence of the R-peptide 
prevents fusion until it is cleaved off by the viral protease during the maturation 
stage of viral replication (thereby activating the Env protein's fusogenic 
ability) [82].  The R-peptide cleavage site of MLV is within an L-V motif in the 
cytoplasmic tail – a motif that is not present in babERV-Fc2-cls cytoplasmic tail 
(Fig. 3.9A).  We therefore hypothesized that babERV-Fc2-cl has an R-peptide, 
but either the MLV protease does not recognize the ERV-Fc R-peptide cleavage 
site or the babERV-Fc2 R-peptide domain has lost the cleavage site.  To 
determine whether babERV-Fc2 Env has an R-peptide, we made four truncations 
of the babERV-Fc2-cl cytoplasmic tail: babERV-Fc2-cl-Δ4AA, babERV-Fc2-cl-
Δ12AA, babERV-Fc2-cl-Δ22AA and babERV-Fc2-cl-Δ29AA (Fig. 3.9A).  A 
chimeric Env was also constructed where the babERV-Fc2-cl cytoplasmic tail 
was replaced with the MLV env cytoplasmic tail (babERV-Fc2-cl-MLVct), which 
contains an R-peptide cleavage site that is recognized and cleaved by the MLV 
protease (Fig. 3.9A).  






























Figure 3.9: Truncation of 22AA off the babERV-Fc2 cytoplasmic tail leads to 
syncytia formation in 293T/17 cells.  (A) Alignment of the MLV cytoplasmic tail 
(ct) (orange), the babERV-Fc2 ct (black), the chimeric babERV-Fc2 Env and 
the four truncation mutants.  The first arrow indicates the MLV R-peptide 
cleavage site. The Second arrow indicates the tyrosine motif. (B) Cell-cell 
fusion in 293T/17 cells transfected with babERV-Fc2 constructs and with 
VSVG, arrows indicate syncytia. Cells co-transfected with GFP expression 
vector.  
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Ectopic expression of babERV-Fc2-cl-Δ22AA in 293T/17 cells led to observable 
syncytia formation (Fig. 3.9B), whereas babERV-Fc2-cl-Δ4AA, babERV-Fc2-cl-
Δ12AA and babERV-Fc2-cl-Δ29AA did not (Fig. 3.9B). This suggests that 
deletion of the C-terminal 22 residues removed a putative R-peptide and 
activated the inherent fusogenicity of the babERV-Fc2 Env protein.  Surprisingly, 
the babERV-Fc2-cl-Δ29AA construct, which would also eliminate the R-peptide, 
did not have the same effect.  This may be due to several unknown factors.  For 
example, the conformation of the Env may have been altered, affecting the Envs 
ability to cause cell-cell fusion.  Alternatively, the cytoplasmic tail is important for 
proper trafficking within a host cell [138],  and therefore babERV-Fc2-cl-Δ29AA 
may not have trafficked properly, which could have led to a reduction in the 
amount of Env at the cell surface and reduced cell-cell fusion.  
MLV particles pseudotyped with babERV-Fc2-cl-Δ22AA were able to 
infect 293T/17 cells (Fig. 3.10).  This indicates that 293T/17 cells express the 
appropriate receptor, and that babERV-Fc2-cl-Δ22AA is able to mediate fusion 
between membranes.  MLV particles pseudotyped with babERV-Fc2-cl-MLVct 
were also able to infect 293T/17 cells at a higher rate than virus pseudotyped 
with babERV-Fc2-cl-Δ22AA, indicating the MLV protease can cleave off the R-
peptide and confirming that there is a possible receptor on 293T/17 cells (Fig. 
3.9).   The decreased rate of infection with babERV-Fc2-cl-Δ22AA may be due to 
a reduced incorporation rate into virions.  It has been shown that a tyrosine (Y) 
motif in the cytoplasmic tail is important for incorporation of the Env into virions 
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Figure 3.10: A repaired and truncated babERV-Fc2 can 
mediate viral infection. Infection of 293T/17 cells with MLV 
particles pseudotyped with babERV-Fc-cl, babERV-Fc2-
Δ22AA, babERV-Fc-cl-MLVct or controls VSVG and No Env. 
N=3. 
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Alternatively, the formation of syncytia in cells expressing babERV-Fc2-cl-Δ22AA 
may have caused cell death resulting in a decreased number of viral particles 
forming.  
To gain insight into the cell tropism of the potential babERV-Fc2, multiple 
cell lines across several species were tested for infectivity.  MLV particles 
pseudotyped with babERV-Fc2-cl-MLVct (MLV-babERV-Fc2-cl-MLVct) were 
used to infect 293T/17 cells (human), HT1080 cells (human), HOS cells (human), 
A549 cells (human), Vero cells (African green monkey (AGM)), LLC-MK2 cells 
(rhesus), MDCK cells (canine), CRFK cells (feline) and DF-1 cells (chicken) (Fig. 
3.11 and 3.12).  MLV-babERV-Fc2-cl-MLVct was able to infect all the human cell 
lines tested, but infection was not detectable in the other, nonhuman cell lines 
(Fig. 3.11 and 3.12), suggesting the presence of a specific receptor on human 
cells but not on the others tested.  This could mean that non-human cells lack the 
receptor or, alternatively, babERV-Fc2-cl-MLVct does not bind to non-human 
orthologs of the receptor.  
 Both gmlERV-Fc-#2 and oafERV-Fc1 are processed into SU and TM (Fig. 
3.4A), indicating they could retain canonical viral functions.  Chimeric Envs 
containing the MLV-ct were made to test infectivity of gmlERV-Fc-#2-MLVct and 
oafERV-Fc1-MLVct against a similar panel of cells as babERV-Fc2-cl-MLVct; 
however, very little to no infection was observed (Fig. 3.12).  Concentrating 
pseudotyped virus also did not result in detectable infection (Fig. 3.13)   These 
results suggest that either the Env proteins are not functional, or that none of the 






















































































































































































Figure 3.11: Human cell lines have a receptor used by babERV-Fc2-cl-MLVct.  
Infectivity of MLV particles pseudotyped with the babERV-Fc2 chimeric Env or 








































































































































Figure 3.12: Human cell lines have a receptor used by babERV-Fc2-cl-MLVct 
but not gmlERV-Fc#2-MLVct and oafERV-Fc1-MLVct.  Infectivity of MLV 
particles pseudotyped with the babERV-Fc2, gmlERV-Fc#2 or oafERV-Fc1 
chimeric Envs or controls VSVG and No Env containing a GFP reporter on a 



















































































































Figure 3.13: Lemur, aardvark and dog ERV-Fc Envs do not infect 
293T/17 cells.  Infection of 293T/17 cells with MLV pseudotyped 
with lemur, aardvark or dog ERV-Fc Envs with MLVcts, controls 
No Env, VSVG and babERV-Fc2-cl-MLVct. Virus was left 
unconcentrated or was concentrated before infections.  N=2.    
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babERV-Fc2 Env confers superinfection resistance to virus pseudotyped 
with babERV-Fc2-cl-MLVct 
 To test the antiviral potential of babERV-Fc2 and the other ERV-Fc Envs, 
a superinfection interference assay was performed.  As negative controls, 
293T/17 cells were transfected with empty vector or a vector expressing 
SIVgp160.  SIV uses CD4 as a primary receptor, which is not expressed on 
293T/17 cells.  In parallel, cells were transfected with the ERV-Fc envs: conERV-
Fc1, HERV-Fc2Δenv, HERV-FcΔenv-MLVct-babSP, babERV-Fc2, babERV-Fc2-
cl-MLVct, cjaERV-Fc3-1, sboERV-Fc3-1, gmlERV-Fc-#1 (data not shown), 
gmlERV-Fc-#2, and oafERV-Fc1.  Transfected cells were challenged with MLV 
particles pseudotyped with no Env, VSVG or babERV-Fc2-cl-MLVct (Fig. 
3.14).  When either babERV-Fc2 or babERV-Fc2-cl-MLVct was expressed in 
target cells, infection by MLV-babERV-Fc-2-cl-MLVct was significantly reduced.  
However, this was not observed with any of the other Envs (Fig.3.14). This 
indicates that babERV-Fc2, which is not cleaved by furin, is still able to interact 
with the putative receptor and block infection.  Importantly, this is the protein 
encoded by the native locus in the baboon genome, suggesting that it could 
function as a restriction factor in baboon cells.  The other ERV-Fc Envs failure to 
block infection could indicate either different receptor use, or that they are non-
















































































































































































































































Figure 3.14: babERV-Fc2 Env blocks infection of MLV pseudotyped with 
babERV-Fc2-cl-MLVct.  Infectivity of MLV particles pseudotyped with 
babERV-Fc2-cl-MLVct, VSVG or No Env when 293T/17 cells are expressing 
ERV-Fc Envs or control Env SIVgp160, N=2. The depicted experiment is a 
representative of 3-6 independent experiments.   
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The dog and panda ERV-Fc Envs are part of the RDR supergroup  
 The envs in this study were classical ERV-Fc-envs except for cfERV-
Fc1(a) and ameERV-Fc1, which appear to have originated from a recombination 
event in the SU, resulting in an Env that branches with ERV-W in phylogenetic  
trees (Fig. 3.15A).  Sequence analyses of cfERV-Fc1(a) and ameERV-Fc1 
revealed the presence of the conserved ASCT2 interaction motif 
SDGGG2XD2XR and other conserved residues upstream of the motif (Fig. 
3.15B).  This suggests that cfERV-Fc1(a) and ameERV-Fc1 may (or did) use 
ASCT2 as a receptor, as seen with other RDR-supergroup Envs that have the 
motif [140]–[143].  When they are used as challenge Envs in a superinfection 
assay the cfERV-Fc1(a) and ameERV-Fc1 Envs are unable to block infection by 
MLV pseudotyped with babERV-Fc2-cl-MLVct (Fig. 3.16).  This indicated that 
they may use a different receptor than babERV-Fc2, supporting cfERV-Fc1(a) 
and ameERV-Fc1s potential use of ASCT2.  To test this possibility, we asked 
whether expression of cfERV-Fc1(a) and ameERV-Fc1 could block infection by 
MPMV, which is part of the RDR-supergroup and uses ASCT2 as a receptor.  
However, the results were inconclusive because the positive control (expression 
of the MPMV Env) did not work in the superinfection interference assay (Fig. 
3.16).  This may be due to transient transfections not being sufficient to block all 
the receptor present or other unknown factors.  Infection data with cfERV-Fc1(a)-
MLVct was also inconclusive, leading to little or no infection in 293T/17 cells (Fig. 
3.13).  This may be due to several factors, such as the Env no longer being 



















Figure 3.15: ameERV-Fc1 and cfERV-Fc1(a) SU domains have the conserved 
ASCT2 binding motif. (A) Neighbor-joining tree of full length ERV-Fc Envs and 
HERV-W.  (B) Alignment of ameERV-Fc1 and cfERV-Fc1(a) with RDR 
supergroup Envs, red box highlights the conserved ASCT2 receptor binding motif 



























































































































































Figure 3.16: cfERV-Fc1(a) and ameERV-Fc1 do not block infection by 
virus pseudotyped with babERV-Fc2-cl-MLVct. Infectivity of MLV particles 
pseudotyped with babERV-Fc2-cl-MLVct, VSVG or No Env and MPMV 
when 293T/17 cells are expressing cfERV-Fc1(a) and ameERV-Fc1.  











Chapter 4: Discussion 
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Here, I have described the discovery and initial characterization of ten 
ERV-Fc env ORFs, which are found as part of partial or full proviruses in which 
the rest of the viral genes have acquired inactivating mutations (Fig. 3.1).  The 
preservation of intact ORFs such as these is suggestive of exaptation for 
cellular/host function.  
An alignment of the ERV-Fc Envs shows they have low identity and 
similarity in SU, but higher similarity and identity in TM (Fig. 3.3A and B).  Codon 
optimized constructs of the envs were transfected into 293T/17 cells and protein 
expression was observed for all of them, though some expressed at higher levels 
than others (Fig. 3.4 A and B).  However, most of the Env precursors were not 
processed properly between the SU and TM, even when there was an intact furin 
cleavage site. Additionally, HERV-Fc2Denv was not glycosylated (Fig. 3.4 A and 
C).   
Several attempts were made to reconstitute functional versions of the 
human and baboon Envs.  For example, adding the signal peptides from 
babERV-Fc2-env or conERV-Fc1-env to HERV-Fc2Denv restored glycosylation; 
however, repairing furin cleavage site mutants in HERV-Fc2Denv and conERV-
Fc1 did not restore processing (Fig. 3.5, 3.6 and 3.7).  
 In the case of babERV-Fc2 Env, restoring a canonical furin cleavage site 
did restore SU-TM processing, but the Env was still not infectious in pseudotyped 
MLV assays (Fig. 3.8 and 3.10).  This led to the hypothesis that ERV-Fc Envs 
may contain an R-peptide, similar to exogenous retroviruses like MLV and MPMV 
[18], [22], [79].  This was shown using truncation mutants and a chimeric Env 
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with the MLVct.  Specifically, removing 22 amino acids from the babERV-Fc Env 
cytoplasmic tail led to the formation of syncytia, and infection was observed with 
this mutant and the chimeric Env (Fig. 3.9 and 3.10).   
A screen of multiple cell lines indicates babERV-Fc2 utilizes a receptor 
present on human cell lines (Fig. 3.11 and 3.12).  The identity of the receptor 
remains unknown.  I made several limited attempts to clone the receptor by a 
gain-of-function screen of a 293T cell cDNA library using a transducible 
puromycin-resistance reporter (see Appendix xxx for a summary of the screen).  
Although a number of puro resistant colonies were obtained in a pilot screen, 
further testing revealed they were false positives likely due to a small background 
infection rate in CRFK cells.  Given the small-scale nature of the screen, further 
efforts are warranted.    
A superinfection interference assay revealed that the uncleaved version of 
babERV-Fc2 Env was able to block infection by virus pseudotyped with babERV-
Fc2-cl-MLVct (Fig. 3.14).  This confirms that the native babERV-Fc Env encoded 
in the baboon genome could function as an antiviral gene.  A similar result was 
recently reported for an intact HERV-T Env ORF found in the human genome 
[134]. 
 Finally, the dog and panda ERV-Fc Envs originated from a recombination 
event and resemble HERV-W (Fig. 3.15A).  In the SU domains of these Envs, the 
proposed ASCT2 receptor interaction motif SDGGGX2DX2R is present, 
suggesting they are part of the RDR supergroup of Envs (3.15B).  I was unable 
to generate infectious pseudotypes with either Env, so it was not possible to 
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confirm that cfERV-Fc1(a) and ameERV-Fc1 use ASCT2 as a receptor directly.  
In the future, assays based on direct binding, such as Co-IP, may be necessary.     
The data reported suggest that the ERV-Fc-env ORFs may have been 
conserved by selection for a host function.  While each of the env ORFs are 
intact, in each case the rest of the ERV-Fc provirus is mutated and the other 
ORFs are disrupted, suggesting there was selective pressure to maintain the env 
ORFs.  All the codon optimized constructs were expressed in transfected cells; 
however, there were multiple defects affecting cleavage at the furin cleavage site 
between the SU and TM, indicating that cleavage and fusion were not maintained 
by selection.  This is supported by the presence of a possible R-peptide in 
babERV-Fc2, which can be assumed to be present on all the ERV-Fc Envs due 
to sequence similarity at the site.  Interestingly, the possible R-peptide in the 
ERV-Fcs does not appear to be cleaved by MLV protease. It would be interesting 
to ask whether there is incompatibility between gammaretroviral Env R-peptides, 
since protease is highly conserved in retroviruses.  The known MLV R-peptide 
cleavage site (L-V) is not present in the ERV-Fc Env cytoplasmic tail.  This raises 
several possibilities, first the babERV-Fc2-env lost the R-peptide cleavage site 
used by MLV and several other Envs [82].  However, the cytoplasmic tail of the 
ERV-Fcs around the predicted area of the R-peptide cleavage site is highly 
conserved and it is unlikely that all the ERV-Fc Envs lost a potential cleavage site 
in the same manner.  As a result, we can speculate that the MLV protease does 
not recognize the cleavage site in the ERV-Fc protease. The incompatibility may 
be due to the age of ERV-Fc (~33 to 15 million years old), during that time there 
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may have been slight changes in the viral protease.  Alternately, ERV-Fc Envs 
may be uniquely adapted to their own protease. The MPMV R-peptide cleavage 
site is between a Y and H, a different site than MLV R-peptide cleavage site, 
which may suggest that the MPMV R-peptide cleavage site is specific to its own 
protease [81].  Thus, a similar adaptation may have occurred in ERV-Fc.  Some 
ERV Envs are fusogenic, without requiring cleavage of an R-peptide.  An 
example being HERV-W/syncytin-1,  which is fusogenic without cleaving off an 
R-peptide, and which does not have the MLV or MPMV R-peptide cleavage site 
in its cytoplasmic tail [90], [144], [145].  However, ERV-Fc does not seem to have 
this ability, as evidenced by babERV-Fc-cl’s inability to mediate fusion.  Currently 
it is unclear why the MLV protease cannot cleave off the ERV-Fc R-peptide; 
however, because of this incompatibility it suggests that ERV-Fc may have been 
fusion incompetent when it first integrated in the baboon genome.         
This fusion deficiency suggests a reason for maintaining the ERV-Fc env 
ORFs.  Cell-cell fusion is unable to occur without a truncated cytoplasmic tail and 
may be damaging to the host, and an ERV Env that can cause this reaction will 
likely be selected against (unless its function involves fusion, as with the 
syncytins).  The fusion deficiency in several of the ERV-Fc Envs was 
compounded by multiple other mutations that interfered with the furin cleavage 
site, deactivating cleavage and further preventing fusion.   The trend of ERV-
Env’s being defective, especially fusion defective, has been observed among 
other ERV Envs that have been implicated in receptor interference antiviral 
activity.  For example, Refrex-1 in cats is truncated before the MSD, but still able 
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to bind to a receptor and block it from use by an exogenous virus when it is 
secreted from the cell [114].  Additionally, when the ancestral Refrex-1 was 
reconstructed there were mutations upstream of the furin cleavage site that 
blocked processing between the SU and TM [131].  This raises the possibility 
that it was also unable to induce cell-cell fusion before it was truncated.  We 
observed the same pattern of furin cleavage inactivation in several of the ERV-Fc 
Envs, where three of the Envs (conERV-Fc1, cjaERV-Fc3 and gmlERV-Fc#1) 
have canonical furin cleavage sites; however, they are not properly processed, 
suggesting other mutations distal to the furin target site prevent cleavage.  These 
mutations likely block by changing the protein structure.  Similar to Refrex-1, the 
mostly open HERV-T Env has mutations that deactivate the furin cleavage site, 
both in and outside the site [134].  Fv4 in mice has a defective fusion peptide and 
cannot mediate viral entry into a cell [126]. All these Envs are fusion defective as 
their furin cleavage sites are inactivated, their fusion peptide is defective, or in 
the case of ERV-Fc, they have an R-peptide that has to be cleaved off.  I 
propose that inactivation of the fusogenic ability of an ERV Env by some or all of 
these mechanisms may be a hallmark of exaptation, particularly for use in an 
antiviral function involving receptor interference.         
 There are multiple examples of ERV Envs being co-opted for an antiviral 
function; which may include the ERV-Fc Envs. This is supported by the ability of 
the native babERV-Fc2 Env (without the reconstructed furin cleavage site and 
with the R-peptide) to block infection by pseudotyped virus carrying the babERV-
Fc2-ENV-cl-MLVct.  These results indicate that cleavage at both places is not 
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necessary for receptor binding and is sufficient to block infection.  This 
observation was also seen with HERV-T, HERV-Ts potentially antiviral Env is not 
cleaved, but it is still able to block infection from an exogenous virus [134].  The 
other ERV-Fc Envs were not able to block infection due to several factors: they 
may not be functional, a human receptor is not used, or they may utilize a 
different receptor than babERV-Fc2.  All have very low identity and similarity, 
especially in the SU, which is responsible for receptor recognition.  This suggests 
that the ERV-Fc Envs may use several different receptors.  We know that ERV-
Fc uses at least two different receptors, one that babERV-Fc2 recognizes and 
another for cfERV-Fc1(a) and ameERV-Fc1.  Their Envs are the result of a 
recombination event and have similarities to Envs from the RDR supergroup, 
including a known receptor interaction motif SDGGGX2DX2R which is not 
present in the other ERV-Fc Envs.   We speculate that endogenization may even 
drive the use of different receptors.  Ecotropic, xenotropic, polytrophic and 
amphotropic strains of MLV use of distinct receptors, CAT-1, Rmc1 and Ram-1 
respectively, even though they are closely related, with the change in receptor 
being caused by only a few mutations [1], [17].  Fv4 is only capable of blocking 
infection by ecotropic MLV [115], [146]. Rmfc1 and Rmfc2 are only able to block 
infection by polytrophic MLV [116], [117].  KoRV-A, is currently in the processes 
of endogenizing in koalas, and uses PiT1 as a receptor [147].  A recent second 
form KoRV-B is not endogenous and uses THTR1 as a receptor even though it is 
closely related to KoRV-A [148]–[150].  The ability of these ERV Envs to block 
only one form of the virus and the fact that they use different receptors from 
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closely related viruses suggests there may have been selection to change 
receptor usage.  The sole purpose of a virus is to infect a host replicate and 
continue to spread.  Therefore, if a receptor is blocked from use, selective 
pressure may drive the use of a new receptor so that the virus continues to 
replicate.  This may be what happened with MLV and KoRV.  It could also 
explain why the ERV-Fc Env SUs are divergent from each other, perhaps as 
ERV-Fc started to endogenize the exogenous form of ERV-Fc adapted to move 
around the receptor block adapting to use multiple different receptors. This 
suggests there may have previously been more ERV-Fc env ORFs.    
Our results suggest the following scenario for the endogenization and 
exaptation of antiviral ERV Envs. As an exogenous retrovirus spreads within a 
species, the acquisition of germline insertions results in ERVs that express Envs 
(Fig. 4.1).  Some of these ERV Envs are able to block the receptor used by the 
exogenous virus protecting the host.  Individuals carrying these ERV-Fc 
insertions may have gained a fitness advantage in the form of viral resistance, 
leading to fixation of the protective alleles (Fig. 4.1).  This selection for the 
fixation of the ERV is driven by the still spreading exogenous virus.  During this 
time, additional modifications to the ERV Env in order to preserve receptor 
binding function and/or to eliminate fusogenicity may have also been selected 
for, as I discovered in the ERV-Fc Envs, and which have been reported for Fv-4, 
Refrex-1 and HERV-T.  In contrast to antiviral ERV Envs, the syncytins retain 
fusion ability [87].  They play an important role in pregnancy; however, having 














Adaptation of the 
ERV Env (e. g. 
loss of fusion)
Figure 4.1: Endogenization and exaptation of antiviral ERV Envs.  On the 
left, spread of an exogenous retrovirus results in an infected germline cell 
and an endogenization event (left green).  As the exogenous virus continues 
to spread it selects for individuals with the ERV who are protected from the 
virus.  This leads to fixation of the ERV within a population.  Pressure from 
the receptor being blocked results in exogenous virus extinction (top right) or 
a receptor switch allowing the exogenous virus to continue spreading in a 
population (bottom right) and may result in a new endogenization event (right 
orange).   
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heavily regulated and expressed only during certain developmental stages and in 
specific tissues [87].  The antiviral ERVs may still be regulated and only 
expressed in certain tissue types but they may be less harmful to the host if they 
are expressed at the wrong time or place due to many of them being fusion 
deficient. 
The fixation of an antiviral ERV may eventually cause the extinction of the 
exogenous virus from the population (Fig. 4.1).  Alternatively, fixation of the 
protective ERV Env in the host population could drive the exogenous virus to 
adapt by switching receptors.  The receptor switch can be achieved either 
through substitutions in the SU, or by recombination and replacement of the 
receptor binding domains with the receptor binding domains of retroviruses that 
use a different receptor, thereby allowing the exogenous virus to continue 
spreading within a population (Fig. 4.1).  The change in the Env leading to a 
receptor switch may also result in infection in a new species.  If another germline 
infection occurs leading to an ERV this model of the establishment of an antiviral 
ERV Env may repeat itself on evolutionary timescales (Fig. 4.1).  The ten loci 
ERV-Fc Envs from eight vertebrate lineages described is this work may 
represent similar but independent occurrences of this endogenization and 
exaptation scenario.  Taken together with examples from mice (Fv-4, rmfc-1 and 
2), chickens (ev3, 6 and 9) and cats (Refrex-1), my results suggest that long-term 
propagation of gammaretroviruses in a population selects for the appearance 
and exaptation of protective ERV loci. 
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I utilized multiple Envs from different species to form a more complete 
picture of what the endogenization process of a family of ERVs may look like, 
and by taking into account our results and previous work done with ERV Envs, 
the above scenario was established.  ERV-Fc is widespread throughout 
mammals, spreading for many millions of years and the model we propose may 
help explain why that is [77].   As discussed above, ERV-Fc Envs are non-
fusogenic from the moment they were endogenized, automatically making them 
good candidates for an antiviral function.  An envelope capable of fusion could be 
harmful for the host and may not be maintained.  A non-fusogenic Env that can 
protect a host from infection may be maintained, and additional mutations that 
further suppress fusion could subsequently be selected (as seen in the ERV-Fc 
Envs and other antiviral ERV Envs).  The second factor that may have 
contributed to the widespread occurrence of ERV-Fc may be due to receptor 
switching, in turn the result of pressure from receptor blocking by an endogenous 
Env, which have broadened the tropism of the ERV (Fig. 4.1).  Recombination, 
as with the ERV-Fc Env in the dog and panda genomes, changed ERV-Fcs 
receptor usage.  Low identity in the SU also suggests the use of multiple 
receptors.  Both of these could lead to the exogenous ERV-Fc crossing over to 
infect multiple different species resulting in the wide spread ERV-Fc fossils we 
now see.     
While there are currently only examples of ERV-Fc-env ORFs in 10 
species, ERV-Fc is so widespread in mammals we hypothesize that historically 
there were more env ORFs that were only transiently open to perform a function 
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when needed, for example, to block a viral receptor. However, if the exogenous 
form of ERV-Fc adapted to use a new receptor, there would no longer be 
pressure to maintain the existing env ORF. We propose the ERV-Fc env ORFs 
were maintained to act as antiviral factors through receptor interference.  
Although there are documented examples of ERV Envs acting as antiviral entry 
inhibitors, this is the first study to couple repeated exaptation of env genes to the 
long-term evolution of a specific viral lineage (ERV-Fc).  Future work focusing on 
identifying the receptor(s) for these Envs could shed light on the exaptive 






















Appendix 1: cDNA Receptor Screen 
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Materials and Methods 
cDNA Library  
 A cDNA library was created from 293T cells using the SMART cDNA 
Library construction kit by Ismael Fofana (Clontech).   cDNA fragments were 
cloned into the pRETRO-Lib vector between the Sfi IA and Sfi IB sites.  
Cell Lines and Media  
Cell lines (HEK293T/17, CRFK) were obtained from the American Type 
Culture Collection (ATCC).  Cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM).  Media was supplemented with 10% fetal bovine 
serum (FBS), 1% L-glutamine (200mM), 1% Penicillin-Streptomycin (10,000 IU- 
10,000 µg/ml) and 2.5% HEPES (1M).  Cells were incubated at 37°C.  
Transduction of cDNA Library into CRFK Cells  
 In order to pseudotyped MLV particles caring the 293T cDNA library, 
293T/17 cells seeded in a 6 well plate for a confluence of ~70%, were transfected 
with pRETRO-Lib, pCIGB and a plasmid containing VSV-G.  The plasmids were 
transfected at a ratio of 3:2:1 respectively using GenJet (SignaGenÒ 
Laboratories), resulting in a total DNA concentration of 2µg/well.   
48 hours after transfection, supernatant was harvested from the 293T/17 
cells centrifuged at 5000rpm for 5 minutes.  CRFK cells seeded in a 12 well plate 
at ~50% confluency were transduced with 250µl of supernatant containing cDNA 




cDNA Library Screen  
 Two days after transduction, CRFK cells were screened with MLV 
particles pseudotyped with babERV-Fc2-cl-MLVct and carrying the puro 
resistance gene (pBABE-puro Addgene).  48 hours after the cDNA containing 
CRFK cells were challenged, they were put under puromycin selection (10µg/µl).  
Cells were kept under selection until puro resistant colonies appeared.  Colonies 
were placed in new plates.  Two subsequent assays were done with puro 
resistant colonies.  First, they were challenged with MLV particles pseudotyped 
with babERV-Fc2-cl-MLVct and containing a GFP reporter gene.  GFP positive 
cells were then counted using Flow.  Second, the genomic DNA from puro 
resistant colonies was harvested using a genomic DNA harvesting kit (Promega).  
The cDNA fragments were then PCR amplified using primers specific to the 
flanking region (Clonetech).   PCR fragments were then gel extracted and blunt 
end cloned into a TOPO vector (ThermoFisher Scientific).  Clones were then sent 




 In order to determine the receptor used by babERV-Fc2 a cDNA screen 
was performed.  A cDNA library was made using mRNA extracted from 293T 
cells, because the highest infection with babERV-Fc2 Env-pseudotyped virus 
was seen in those cells (Fig. 3.11).  The cDNA library was then transduced into 
CRFK cells because babERV-Fc2 is unable to infect CRFK cells and there is low 
background (Fig. 3.11).  CRFK cells transduced with the 293T cDNA library were 
challenged with MLV particles pseudotyped with babERV-Fc2-cl-MLVct carrying 
the puro resistant gene.  Puromycin selection was then used to screen for CRFK 
cells that were then susceptible to infection by MLV particles pseudotyped with 
babERV-Fc2-cl-MLVct.  Five separate cDNA screens were done.  From those 
screens 25 resistant colonies were isolated and further tested (Fig. A1.1).   
Resistant clones were reinfected by MLV-babERV-Fc2-cl-MLVct, however there 
was not a significant improvement in susceptibility to infection when compared to 
CRFK cells without the 293T cDNA library (Fig. A1.1).  This indicates that cDNAs 
present in these puro resistant CRFK colonies did not encode the receptor used 
by babERV-Fc2, and are most likely the result of background infection.  This is 
supported by the sequencing results from the puro resistant colonies.  While 
partial gene sequences were obtained, none were good receptor candidates 
(Fig.A1.1).  Gamma Envs are known to used membrane proteins that have 
multiple membrane spanning domains and are often transporters [17].  Further 
larger scale screens will need to be done in order to determine the receptor used 





Colony Sequencing Results 
2C1 Vector
2C3 histidine triad nucleotide binding protein 1
7C3 None
8B1 Actin regulator (ENAH)
9A2
nucleophosmin (nucleolar phosphoprotein B23, 
numatin), and FLJ95438, cell division cycle 40 
homolog
9B3 Vector
9C4 cyclin B1 interacting protein 1, and Thioredoxin
10B2
ATP synthase, H+ trasporting , mitochondrial Fo
complex, subunit F6
10B3 CGG triplet repeate binding protein 1
10B4 actin regulator (ENAH)
10C4
metabolism of cobalamin associated (MMACHC) 
trascript varient 1
11A4 Ribosomal protein S4
11B3 Ribosomal protein S4
12B3 Ribosomal protein S4
















































































Figure A1.1: cDNA library screen results.  (A) A list of all puromycin 
resistant colonies, named for the plate#:row:well# they were found in, listed 
also is the sequencing results obtained from each colony.  (B) Reinfection 
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